INNOVATE Corp.: Form 10-Q for the period ended Jun 30, 2026
Filed with the SEC on Aug 6, 2026 and accepted by EDGAR at Aug 6, 2026, 16:22 ET.
Management's discussion and analysis
As filed, 134,151 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
You should read the following discussion and analysis of our financial condition and results of operations together with the consolidated annual audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 26, 2026 (the "2025 Annual Report"), and the unaudited condensed consolidated financial statements and related notes included in this Quarterly Report on Form 10-Q. Some of the information contained in this discussion and analysis includes forward-looking statements that involve risks and uncertainties. You should review the "Risk Factors" section in our 2025 Annual Report as well as below in this Form 10-Q and the section below entitled "Special Note Regarding Forward-Looking Statements" for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.
Unless the context otherwise requires, in this Quarterly Report on Form 10-Q, "INNOVATE" means INNOVATE Corp. and the "Company," "we", "us" and "our" mean INNOVATE together with its consolidated subsidiaries. "U.S. GAAP" means accounting principles generally accepted in the United States of America.
We are currently pursuing highly substantial asset dispositions, including a sales process for all or substantially all of DBMG's assets or equity interests (the "Potential DBMG Sale") and the Spectrum Merger. We have also made substantial changes to our debt arrangements and other liabilities and expect to make further changes. These ongoing actions will substantially alter our business, prospects, cash flow, results of operations and financial position going forward and all information herein should be evaluated in light of these changes, and potential changes.
In particular, the anticipated Spectrum Merger, if completed, and any Potential DBMG Sale, if successfully negotiated and closed, would substantially reshape our business and, as a result, our past financial results may not be a reliable indicator of future performance and historical trends should not be unduly used to anticipate results or trends in future periods.
If the Spectrum Merger is consummated and a Potential DBMG Sale is negotiated and consummated, it would eliminate substantially all of our consolidated operating revenue, and our assets would consist largely of net cash or other proceeds of the Potential DBMG Sale, remaining after required repayments of indebtedness (of which we currently expect there may be none), our minority interest in the Surviving Entity, our remaining Life Sciences segment and limited remaining Other segment activities.
Thereafter, our primary source of income would be expected to be any dividends or distributions from our minority investments and interest earned on our marketable securities and cash and cash equivalents, as we pursued strategic opportunities.
Additionally, the Potential DBMG Sale would introduce additional liquidity risk because its consummation would trigger the Change in Control provisions of the DBMG Credit Agreement and result in repayment or other payment obligations under certain instruments, including the Revolving Line of Credit, the 10.50% 2027 Senior Secured Notes and the 2027 Convertible Notes. If cash consideration for any Potential DBMG Sale and other available funds are not sufficient or available when required, a shortfall could prevent or delay the closing of any Potential DBMG Sale, result in defaults or cross-defaults, accelerate other obligations and further impair the Company’s ability to continue as a going concern. If we fail to consummate sufficient asset sales, including the Potential DBMG Sale, or the value of the consideration received is less than anticipated, we would be in violation of covenants under our indebtedness (absent waivers), would likely be unable to satisfy our debt service obligations and may be unable to continue as a going concern.
Our Business and Our Operations
We are a diversified holding company with principal operations conducted through three operating platforms or reportable segments as of June 30, 2026: Infrastructure ("DBMG"), Life Sciences ("Pansend"), and Spectrum, plus our Other segment, which includes businesses that do not meet the separately reportable segment thresholds.
For additional information on our business, refer to Note 1. Organization and Business to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference.
We continually evaluate strategic and business alternatives within our operating segments, which may include the following: operating, growing or acquiring additional assets or businesses related to current or historical operations; or winding down or selling our existing operations. In the longer term, we may evaluate opportunities to acquire assets or businesses unrelated to our current or historical operations. In the event we were to enter into a strategic transaction to sell any of our existing operations, our intention is to use available proceeds from such transaction to address our capital structure.
During 2026, as part of our strategic process, we have engaged in and are contemplating several transactions that had or will have an effect on the results of operations and financial condition of our business and individual segments.
Recent Developments
Spectrum
During the second quarter of 2026, our Spectrum segment met the criteria for classification as held for sale in accordance with ASC 360-10 Property, Plant, and Equipment ("ASC 360-10"). As a result, the assets and liabilities of the Spectrum segment are presented as held for sale in the current period, and the prior period assets and liabilities of the Spectrum segment have been reclassified as held for sale for comparability purposes. While the Spectrum segment met the criteria for held for sale classification, it did not meet the criteria for classification as discontinued operations in accordance with ASC 205-20, Presentation of Financial Statements - Discontinued Operations ("ASC 205-20"), as the anticipated disposal does not represent a strategic shift that will have a major effect on our operations and financial results.
On May 29, 2026, HC2 Broadcasting Holdings Inc. (“Broadcasting”) closed on a refinancing transaction. In addition, Broadcasting and HC2 Broadcasting Holdco, LLC (“HC2 Holdco”), subsidiaries of INNOVATE, entered into a definitive agreement pursuant to which INNOVATE will sell a controlling interest in Broadcasting to CONX CORP. (“CONX”), subject to the satisfaction of customary closing conditions, including the receipt of required regulatory approvals. After the closing of the transaction, it is expected that CONX will own approximately 75% of Broadcasting and INNOVATE will own approximately 25% of Broadcasting through HC2 Holdco.
The Closing is subject to customary conditions, including (a) receipt of regulatory approvals, including certain approvals of the Federal Communications Commission ("FCC") and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and (b) that the obligations under the New Spectrum Loan Agreement (as defined in Note 3. Assets and Liabilities Held for Sale) shall not have been declared due and payable.
The Merger Agreement provides customary termination rights for the parties, including if the Merger has not occurred on or prior to November 29, 2026, subject to two potential extensions to March 1, 2027 and May 29, 2027 in the event the only condition to the Spectrum Merger that remains unsatisfied as of such dates is the receipt of certain regulatory approvals and certain other exceptions, and contains certain indemnification obligations by the parties thereto in connection with breaches of certain representations and warranties and certain covenants contained in the Merger Agreement, subject to certain exceptions.
Refer to Note 3. Assets and Liabilities Held for Sale to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference.
Corporate Debt
The 10.50% 2027 Senior Secured Notes Indenture required us to meet certain milestones with respect to strategic alternatives for our operating subsidiaries, including asset sales generating at least $150 million in net proceeds, to be applied to the 10.50% 2027 Senior Secured Notes, such that by September 1, 2025 the Company needed to have a bona fide bid or term sheet related to a potential sale. The September 1, 2025 milestone was not reached, and in accordance with the indenture, we were thus required to commence a sales process for DBMG. The sales process for DBMG, which has been initiated and is proceeding, has separate milestone requirements, which we had either met or extended as of June 30, 2026, and we were in compliance with the milestone covenants requirements. Refer to Note 12. Debt Obligations to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information on our 10.50% 2027 Senior Secured Notes and other Corporate debt.
The covenants contained in the DBMG Credit Agreement contain a Change in Control clause, which would constitute an Event of Default, both as defined in the DBMG Credit Agreement, which could accelerate the maturity of our Infrastructure segment's debt in the future upon certain events, including a sale of DBMG.
Subsequent to quarter end, interest due on August 1, 2026 on our 10.50% 2027 Senior Secured Notes and 2027 Convertible Notes, held by consenting holders, was paid in kind, and those holders received additional notes as a 1.5% consent fee. Refer to Note 22. Subsequent Events to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information.
DBMG Dividend
Subsequent to quarter end, on July 8, 2026, DBMG declared a $12.0 million cash dividend which was paid on August 3, 2026, of which INNOVATE received $11.0 million.
Life Sciences - Financing
On July 31, 2026, the maturity of R2 Technologies' secured promissory note with Lancer was extended from August 1, 2026 to the earlier of December 31, 2026, or the occurrence of (i) a Change of Control (as defined in the amended note) or (ii) the sale of all or substantially all of the assets of R2 Technologies. The total principal balance as of June 30, 2026, which includes capitalized interest and fees was $50.9 million.
As of June 30, 2026, there were $7.8 million in intercompany 13.0% convertible notes with R2 Technologies. On July 28, 2026, R2 Technologies' preferred equity outstanding, and outstanding convertible promissory notes held by Pansend were converted to common equity. As a result of the conversion, Pansend's controlling interest in R2 Technologies increased from 80.8%, prior to the transaction, to 85.0%. Refer to Note 22. Subsequent Events and to Note 16. Temporary Equity to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which are incorporated herein by reference, for additional information on R2 Technologies' convertible preferred stock and convertible notes.
Series A-3 and Series A-4 Preferred Stock
On June 30, 2026, the holder of our outstanding Series A-3 and Series A-4 Preferred Stock delivered a redemption notice requiring the Company to redeem those shares at the redemption price (accrued value plus all accrued and unpaid dividends, to the extent not included in the accrued value). The Company did not have sufficient legally available funds to pay the redemption price in cash or other assets. Under the terms of the certificates of designation, because the preferred shares were not redeemed when required, they remain outstanding and continue to be entitled to all powers, designations, preferences, and other rights, including the right to accrual and payment of dividends and conversion rights. For a description of the terms of the Series A-3 and A-4 Preferred Stock, including the dividend, accretion, conversion, and redemption mechanics, refer to Note 16. Temporary Equity to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information.
Equity Method Investments
MediBeacon
On March 31, 2026, MediBeacon received the European Union ("EU") CE mark certification under the EU Medical Device Regulation ("MDR") for its TGFRTM Monitor and TGFRTM Reusable sensor. The certification confirms that the Monitor and Sensor have met the robust safety, quality, and performance standards required under EU MDR.
As of June 30, 2026, Pansend's carrying amount of its investment in MediBeacon remained at zero, inclusive of the $0.5 million in secured promissory notes which has been offset against recognized equity method losses, and Pansend has cumulative unrecognized equity method losses relating to MediBeacon of $22.6 million. Subsequent to quarter end, on July 2, 2026, the $0.5 million principal note due to Pansend, which had a maturity of July 5, 2026, together with all accrued and unpaid interest of $0.4 million was converted into a new convertible note of principal amount $0.9 million. Refer to Note 22. Subsequent Events to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information.
Additional Subsequent Events
Refer to Note 22. Subsequent Events to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information on other events that occurred subsequent to June 30, 2026.
Cyclical Patterns
Our segments' operations can be highly cyclical. Our volume of business in our Infrastructure segment may be adversely affected by declines or delays in projects, which may vary by geographic region. Project schedules, particularly in connection with large, complex, and longer-term projects can also create fluctuations in the services provided, which may adversely affect us in any given period.
For example, in connection with larger, more complicated projects, the timing of obtaining permits and other approvals may be delayed, and we may need to maintain a portion of our workforce and equipment in an underutilized capacity to ensure we are strategically positioned to deliver on such projects when they move forward.
Examples of other items that may cause our results or demand for our services to fluctuate materially from quarter to quarter include: weather or project site conditions; customer spending patterns, including seasonal trends, and the financial condition of our customers and their access to capital; our profit margins on projects performed during any particular period; rising interest rates and inflation; and regulatory, economic, political and market conditions on a regional, national or global scale.
Accordingly, our operating results in any particular period may not be indicative of the results that can be expected for any other period.
Financial Presentation Background
In the below section within this Management’s Discussion and Analysis of Financial Condition and Results of Operations, we compare, pursuant to U.S. GAAP and SEC disclosure rules, the Company’s results of operations for the three and six months ended June 30, 2026, as compared to the three and six months ended June 30, 2025.
We are currently pursuing highly substantial asset dispositions, including a sales process for all or substantially all of DBMG's assets or equity interests, and the Spectrum Merger. We have also made changes to our debt arrangements and other liabilities, including following June 30, 2026, and expect to make further changes. These ongoing actions will substantially alter our business, prospects, cash flow and financial position going forward and all information herein should be evaluated in light of these changes and potential changes. Refer to Note 22. Subsequent Events to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for further information.
Results of Operations
The following table summarizes our results of continuing operations (in millions):
| Revenue | Three Months Ended June 30, 2026 | 2025 | Increase / (Decrease) | Six Months Ended June 30, 2026 | 2025 | Increase / (Decrease) |
|---|---|---|---|---|---|---|
| Infrastructure | $414.0 | $233.1 | $180.9 | $771.9 | $498.0 | $273.9 |
| Life Sciences | 2.2 | 3.2 | (1.0) | 3.8 | 6.3 | (2.5) |
| Spectrum | 5.4 | 5.7 | (0.3) | 10.7 | 11.9 | (1.2) |
| Total revenue | $421.6 | $242.0 | $179.6 | $786.4 | $516.2 | $270.2 |
| Income (loss) from operations | ||||||
| Infrastructure | $39.5 | $10.6 | $28.9 | $55.5 | $19.7 | $35.8 |
| Life Sciences | (0.7) | (2.8) | 2.1 | (2.9) | (5.8) | 2.9 |
| Spectrum | (1.6) | (0.3) | (1.3) | (2.0) | (0.1) | (1.9) |
| Non-Operating Corporate | (2.7) | (2.6) | (0.1) | (6.1) | (5.5) | (0.6) |
| Total income from operations | $34.5 | $4.9 | $29.6 | $44.5 | $8.3 | $36.2 |
| Interest expense | (27.6) | (21.4) | (6.2) | (52.1) | (41.6) | (10.5) |
| Gain (loss) on extinguishment of debt | 18.4 | (0.3) | 18.7 | 18.4 | (0.3) | 18.7 |
| Loss from equity investees | — | — | — | — | (5.9) | 5.9 |
| Other income, net | 0.2 | — | 0.2 | 0.5 | 4.0 | (3.5) |
| Income (loss) from operations before income taxes | $25.5 | $(16.8) | $42.3 | $11.3 | $(35.5) | $46.8 |
| Income tax expense | (13.1) | (4.2) | (8.9) | (16.0) | (11.3) | (4.7) |
| Net income (loss) | $12.4 | $(21.0) | $33.4 | $(4.7) | $(46.8) | $42.1 |
| Net (income) loss attributable to non-controlling interests and redeemable non-controlling interests | (1.7) | 1.2 | (2.9) | (1.4) | 2.5 | (3.9) |
| Net income (loss) attributable to INNOVATE Corp. | $10.7 | $(19.8) | $30.5 | $(6.1) | $(44.3) | $38.2 |
| Less: Preferred stock dividends | 0.3 | 2.2 | (1.9) | 0.7 | 2.5 | (1.8) |
| Net income (loss) attributable to common stockholders and participating preferred stockholders | $10.4 | $(22.0) | $32.4 | $(6.8) | $(46.8) | $40.0 |
Revenue: Revenue for the three months ended June 30, 2026, increased $179.6 million to $421.6 million from $242.0 million for the three months ended June 30, 2025. Revenue for the six months ended June 30, 2026, increased $270.2 million to $786.4 million from $516.2 million for the six months ended June 30, 2025. The increases were primarily driven by our Infrastructure segment, which was partially offset by decreases at our Life Sciences and Spectrum segments. The increase at our Infrastructure segment was primarily driven by the timing and size of projects at DBMG's commercial structural steel fabrication and erection business, which had increased activity subsequent to the comparable period on certain large construction projects, which was partially offset by a decrease at the industrial maintenance and repair business due to the timing and size of projects, which had increased activity in the comparable period on certain large construction projects that have since been completed. The decrease at our Life Sciences segment was attributable to R2 Technologies, primarily driven by net decreases in Glacial system unit sales due to liquidity constraints. The decrease at our Spectrum segment was primarily driven by the termination of a few networks and individual markets subsequent to the comparable period, partially offset by the launch of new networks.
Income from operations: Income from operations for the three months ended June 30, 2026 increased $29.6 million to $34.5 million from $4.9 million for the three months ended June 30, 2025. The increase was due to a net increase in gross profit of $33.9 million, a decrease in other operating losses of $1.2 million and a decrease in depreciation and amortization of $0.9 million, partially offset by a net increase in selling, general and administrative ("SG&A") expenses of $6.4 million. The net increase in gross profit was primarily driven by our Infrastructure segment due to timing and size of projects in the current period, which had increased activity subsequent to the comparable period, combined with changes in the estimate of the cost to complete those projects recognized in the ordinary course driven by efficiencies recognized around certain projects, partially offset by our Life Sciences segment due to the decrease in revenue. The decrease in other operating losses was driven by our Infrastructure segment due to unrepeated losses on the sales of various properties and an unrepeated loss on lease modification in the comparable period. The decrease in depreciation and amortization was primarily driven by the Spectrum segment's cessation of depreciation and amortization on its long-lived assets subsequent to its classification as held for sale on May 29, 2026. The increase in SG&A was primarily driven by our Infrastructure segment, primarily due to the timing of compensation-related expenses, and an increase at our Spectrum segment primarily driven by transaction-related expenses incurred in the current period. These increases in SG&A were partially offset by a decrease in SG&A at our Life Sciences segment due to reductions in compensation-related expenses at R2 Technologies and Pansend.
Income from operations for the six months ended June 30, 2026, increased $36.2 million to $44.5 million from $8.3 million for the six months ended June 30, 2025. The increase was primarily due to a net increase in gross profit of $41.9 million, a decrease in other operating losses of $1.2 million and a decrease in depreciation and amortization of $1.1 million, partially offset by a net increase in SG&A expenses of $8.0 million. The net increase in gross profit was primarily driven by our Infrastructure segment due to timing and size of projects in the current period, which had increased activity subsequent to the comparable period, combined with changes in the estimate of the cost to complete those projects recognized in the ordinary course driven by efficiencies recognized around certain projects, partially offset by our Spectrum and Life Sciences segments due to the decreases in revenue. The decrease in other operating losses was driven by our Infrastructure segment due to unrepeated losses on the sales of various properties and an unrepeated loss on lease modification in the comparable period. The decrease in depreciation and amortization was primarily driven by the Spectrum segment's cessation of depreciation and amortization on its long-lived assets subsequent to its classification as held for sale on May 29, 2026. The increase in SG&A was primarily driven by our Infrastructure segment, primarily due to the timing of compensation-related expenses, an increase at our Spectrum segment primarily driven by transaction-related expenses incurred in the current period, and an increase at our Non-Operating Corporate segment primarily driven by expenses related to potential dispositions and strategic transactions in the current period. These increases in SG&A were partially offset by a decrease in SG&A at our Life Sciences segment due to reductions in compensation-related expenses at R2 Technologies and Pansend.
Interest expense: Interest expense for the three months ended June 30, 2026 increased $6.2 million to $27.6 million from $21.4 million for the three months ended June 30, 2025. Interest expense for the six months ended June 30, 2026, increased $10.5 million to $52.1 million from $41.6 million for the six months ended June 30, 2025. The increase in interest expense was primarily driven by our Non-Operating Corporate and Spectrum segments. The increase at our Non-Operating Corporate segment was due to the indebtedness refinancing transactions completed subsequent to the comparable period, which resulted in increased principal balances due to the capitalization of fees and interest, and certain increases in interest rates, leading to increased interest expense including amortization of fees. The increase at our Spectrum segment was primarily due to the New Spectrum Loan Agreement entered into in the current period, under which the effective interest rate includes the stated interest rate and accretion of a contractually specified minimum return on the New Spectrum Loan Agreement through its stated maturity. These increases were partially offset by our Life Sciences segment due to the refinancing of their debt subsequent to the comparable period, which removed certain exit and default fees and decreased the stated interest rate, which was partially offset by the higher outstanding principal amount. The increase in interest expense was also partially offset by our Infrastructure segment primarily driven by the net decrease in principal balance.
Loss from equity investees: Loss from equity investees for the six months ended June 30, 2026, decreased to zero from $5.9 million for the six months ended June 30, 2025. The decrease was due to a decrease in losses recognized from MediBeacon. During the six months ended June 30, 2025, as a result of the unrepeated equity transactions that occurred upon FDA approval of MediBeacon's TGFR in the comparable period, Pansend's basis in MediBeacon increased by $5.9 million, consisting of a $4.4 million step-up gain and $1.5 million from the conversion of accrued interest on Pansend's convertible notes with MediBeacon, resulting in Pansend recognizing $5.9 million of equity method losses that were previously unrecognized. As of both June 30, 2026 and June 30, 2025, Pansend's net carrying amount of its investment in MediBeacon was zero, and Pansend had unrecognized losses from this investment. Refer to Note 7. Investments to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information on our equity investments.
Gain (loss) on extinguishment of debt: Gain on extinguishment of debt for the three and six months ended June 30, 2026 increased $18.7 million to a gain of $18.4 million from a loss of $0.3 million for the three and six months ended June 30, 2025. The gain on extinguishment of debt for the three and six months ended June 30, 2026 related to the Spectrum refinancing transaction during the current period. Refer to Note 3. Assets and Liabilities Held for Sale to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information on the refinancing transaction. The loss on extinguishment of debt of $0.3 million for the three and six months ended June 30, 2025 related to our Infrastructure segment's refinancing.
Other income, net: Other income, net for the three months ended June 30, 2026 increased to $0.2 million from zero for the three months ended June 30, 2025. The increase was primarily driven by an increase in interest income and a decrease in foreign currency translation losses from our Infrastructure segment, which was partially offset by a decrease in unrealized fair value gains on marketable securities at our Non-Operating Corporate segment.
Other income, net for the six months ended June 30, 2026, decreased $3.5 million to $0.5 million from $4.0 million for the six months ended June 30, 2025. The decrease was primarily driven by the unrepeated $4.4 million step-up gain following MediBeacon's FDA approval in the comparable period and a decrease in unrealized fair value gains on marketable securities at our Non-Operating Corporate segment. These decreases were partially offset by an unrepeated legal settlement expense at our Non-Operating Corporate segment in the comparable period, as well as an increase in interest income and a decrease in foreign currency translation losses from our Infrastructure segment. Refer to Note 21. Supplementary Financial Information to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information on other income, net.
Income tax expense: Income tax expense for the three months ended June 30, 2026 increased $8.9 million to $13.1 million from $4.2 million for the three months ended June 30, 2025. Income tax expense for the six months ended June 30, 2026, increased $4.7 million to $16.0 million from $11.3 million for the six months ended June 30, 2025. The increases in tax expense were primarily driven by higher pre-tax income combined with an increase in the annual effective tax rate, including as a result of limitations on the utilization of net operating losses ("NOL") by INNOVATE's U.S. consolidated group under Internal Revenue Code Section 382 and the Tax Cuts and Jobs Act's 80 percent limitation on NOLs incurred after 2017.
Segment Results of Operations
In the Company's Condensed Consolidated Financial Statements, other operating (income) loss includes: (i) (gain) loss on sale or disposal of assets; (ii) lease termination costs and (gains) losses on lease modifications; and (iii) asset impairment expense; as applicable. Each table summarizes the results of operations of our operating segments (in millions).
Infrastructure Segment
| Three Months Ended June 30, 2026 | 2025 | Increase / (Decrease) | Six Months Ended June 30, 2026 | 2025 | Increase / (Decrease) | |
|---|---|---|---|---|---|---|
| Revenue | $414.0 | $233.1 | $180.9 | $771.9 | $498.0 | $273.9 |
| Cost of revenue | 337.6 | 191.4 | 146.2 | 644.6 | 414.9 | 229.7 |
| Selling, general and administrative | 34.1 | 26.8 | 7.3 | 66.1 | 56.1 | 10.0 |
| Depreciation and amortization | 2.8 | 3.1 | (0.3) | 5.7 | 6.2 | (0.5) |
| Other operating loss | — | 1.2 | (1.2) | — | 1.1 | (1.1) |
| Income from operations | $39.5 | $10.6 | $28.9 | $55.5 | $19.7 | $35.8 |
Revenue: Revenue for the three months ended June 30, 2026 increased $180.9 million to $414.0 million from $233.1 million for the three months ended June 30, 2025. Revenue for the six months ended June 30, 2026, increased $273.9 million to $771.9 million from $498.0 million for the six months ended June 30, 2025. The increases were primarily driven by the timing and size of projects at DBMG's commercial structural steel fabrication and erection business, which had increased activity subsequent to the comparable period on certain large construction projects, combined with changes in the estimate of the cost to complete those projects recognized in the ordinary course driven by efficiencies recognized around certain projects, and to a lesser extent, at the construction modeling and detailing business and the new modular business. The increases were partially offset by a decrease at the industrial maintenance and repair business due to the timing and size of projects, which had increased activity in the comparable period on certain large construction projects that have since been completed.
Cost of revenue: Cost of revenue for the three months ended June 30, 2026 increased $146.2 million to $337.6 million from $191.4 million for the three months ended June 30, 2025. The increase was primarily driven by the increase in revenue at DBMG's commercial structural steel fabrication and erection business due to the increased activity subsequent to the comparable period on certain large construction projects, and to a lesser extent, an increase at the new modular business and the construction modeling and detailing business due to the increases in revenue.
Cost of revenue for the six months ended June 30, 2026, increased $229.7 million to $644.6 million from $414.9 million for the six months ended June 30, 2025. The increase was primarily driven by the increase in revenue at DBMG's commercial structural steel fabrication and erection business due to the increased activity subsequent to the comparable period on certain large construction projects, and to a lesser extent, an increase at the new modular business and the construction modeling and detailing business due to the increases in revenue. The increases in cost of revenue were partially offset by a decrease at the industrial maintenance and repair business as a result of the decrease in revenue due to the timing of project activity on certain large construction projects that have been completed subsequent to the comparable period.
Selling, general and administrative: Selling, general and administrative expense for the three months ended June 30, 2026 increased $7.3 million to $34.1 million from $26.8 million for the three months ended June 30, 2025. Selling, general and administrative expense for the six months ended June 30, 2026, increased $10.0 million to $66.1 million from $56.1 million for the six months ended June 30, 2025. The increases were primarily driven by the timing of compensation-related expenses.
Depreciation and amortization: Depreciation and amortization for the three months ended June 30, 2026 decreased $0.3 million to $2.8 million from $3.1 million for the three months ended June 30, 2025. Depreciation and amortization for the six months ended June 30, 2026 decreased $0.5 million to $5.7 million from $6.2 million for the six months ended June 30, 2025. The decreases were primarily driven by a decrease in intangible amortization at our Banker Steel business as a result of intangible assets that have become fully amortized subsequent to the comparable periods.
Other operating loss: Other operating loss for the three months ended June 30, 2026 decreased to zero from $1.2 million for the three months ended June 30, 2025. Other operating loss for the six months ended June 30, 2026 decreased to zero from $1.1 million for the six months ended June 30, 2025. Other operating loss in the comparable periods related to unrepeated losses on the sales of various properties and an unrepeated loss on lease modification.
Life Sciences Segment
| Three Months Ended June 30, 2026 | 2025 | Increase / (Decrease) | Six Months Ended June 30, 2026 | 2025 | Increase / (Decrease) | |
|---|---|---|---|---|---|---|
| Revenue | $2.2 | $3.2 | $(1.0) | $3.8 | $6.3 | $(2.5) |
| Cost of revenue | 1.3 | 2.1 | (0.8) | 2.7 | 4.4 | (1.7) |
| Selling, general and administrative | 1.6 | 3.8 | (2.2) | 3.9 | 7.5 | (3.6) |
| Depreciation and amortization | — | 0.1 | (0.1) | 0.1 | 0.2 | (0.1) |
| Loss from operations | $(0.7) | $(2.8) | $2.1 | $(2.9) | $(5.8) | $2.9 |
Revenue: Revenue for the three months ended June 30, 2026 decreased $1.0 million to $2.2 million from $3.2 million for the three months ended June 30, 2025. The decrease was attributable to R2 Technologies, primarily driven by decreases in Glacial fx unit sales in North America and Glacial Spa unit sales outside North America due to liquidity constraints.
Revenue for the six months ended June 30, 2026, decreased $2.5 million to $3.8 million from $6.3 million for the six months ended June 30, 2025. The decrease in revenue was attributable to R2 Technologies, primarily driven by decreases in Glacial fx and Glacial Rx unit sales in North America due to liquidity constraints.
Cost of revenue: Cost of revenue for the three months ended June 30, 2026 decreased $0.8 million to $1.3 million from $2.1 million for the three months ended June 30, 2025. Cost of revenue for the six months ended June 30, 2026, decreased $1.7 million to $2.7 million from $4.4 million for the six months ended June 30, 2025. The decreases in cost of revenue were attributable to R2 Technologies, primarily driven by the decrease in revenue noted above and, to a lesser extent, the related decreases in warranty expenses and royalty expenses.
Selling, general and administrative: Selling, general and administrative expense for the three months ended June 30, 2026 decreased $2.2 million to $1.6 million from $3.8 million for the three months ended June 30, 2025. Selling, general and administrative expense for the six months ended June 30, 2026, decreased $3.6 million to $3.9 million from $7.5 million for the six months ended June 30, 2025. The decreases were primarily driven by reductions in compensation-related expenses at R2 Technologies and Pansend.
Spectrum Segment
| Three Months Ended June 30, 2026 | 2025 | Increase / (Decrease) | Six Months Ended June 30, 2026 | 2025 | Increase / (Decrease) | |
|---|---|---|---|---|---|---|
| Revenue | $5.4 | $5.7 | $(0.3) | $10.7 | $11.9 | $(1.2) |
| Cost of revenue | 3.2 | 2.9 | 0.3 | 6.1 | 5.8 | 0.3 |
| Selling, general and administrative | 3.1 | 1.9 | 1.2 | 4.8 | 3.8 | 1.0 |
| Depreciation and amortization | 0.7 | 1.2 | (0.5) | 1.9 | 2.4 | (0.5) |
| Other operating income | — | — | — | (0.1) | — | (0.1) |
| (Loss) income from operations | $(1.6) | $(0.3) | $(1.3) | $(2.0) | $(0.1) | $(1.9) |
Revenue: Revenue for the three months ended June 30, 2026 decreased $0.3 million to $5.4 million from $5.7 million for the three months ended June 30, 2025. Revenue for the six months ended June 30, 2026, decreased $1.2 million to $10.7 million from $11.9 million for the six months ended June 30, 2025. The decreases were primarily driven by the termination of a few networks and individual markets subsequent to the comparable period, which was partially offset by the launch of new networks.
Cost of revenue: Cost of revenue for the three months ended June 30, 2026 increased slightly by $0.3 million to $3.2 million from $2.9 million for the three months ended June 30, 2025. Cost of revenue for the six months ended June 30, 2026 increased slightly by $0.3 million to $6.1 million from $5.8 million for the six months ended June 30, 2025.
Selling, general and administrative: Selling, general and administrative expense for the three months ended June 30, 2026 increased $1.2 million to $3.1 million from $1.9 million for the three months ended June 30, 2025. Selling, general and administrative for the six months ended June 30, 2026 increased $1.0 million to $4.8 million from $3.8 million for the six months ended June 30, 2025. The increases were primarily driven by transaction-related expenses incurred in the current period.
Depreciation and amortization: Depreciation and amortization for the three months ended June 30, 2026 decreased $0.5 million to $0.7 million from $1.2 million for the three months ended June 30, 2025. Depreciation and amortization for the six months ended June 30, 2026 decreased $0.5 million to $1.9 million from $2.4 million for the six months ended June 30, 2025. The decreases were primarily driven by the cessation of depreciation and amortization on long-lived assets subsequent to May 29, 2026, as a result of the Spectrum segment's classification as held for sale.
Non-Operating Corporate
| Three Months Ended June 30, 2026 | 2025 | Increase / (Decrease) | Six Months Ended June 30, 2026 | 2025 | Increase / (Decrease) | |
|---|---|---|---|---|---|---|
| Selling, general and administrative | $2.7 | $2.6 | $0.1 | $6.1 | $5.5 | $0.6 |
| Loss from operations | $(2.7) | $(2.6) | $(0.1) | $(6.1) | $(5.5) | $(0.6) |
Selling, general and administrative: Selling, general and administrative expenses for the three months ended June 30, 2026 increased $0.1 million to $2.7 million from $2.6 million for the three months ended June 30, 2025. Selling, general and administrative expenses for the six months ended June 30, 2026 increased $0.6 million to $6.1 million from $5.5 million for the six months ended June 30, 2025. The increases were primarily driven by expenses incurred in the current period related to potential dispositions and strategic transactions, which were partially offset by a decrease in compensation-related expenses.
Loss from Equity Investees
| Six Months Ended June 30, 2026 | 2025 | (Increase) / Decrease | |
|---|---|---|---|
| Life Sciences | $— | $(5.9) | $5.9 |
| Loss from equity investees | $— | $(5.9) | $5.9 |
Life Sciences: Loss from equity investees within our Life Sciences segment for the six months ended June 30, 2026, decreased $5.9 million to zero from $5.9 million for the six months ended June 30, 2025. The decrease in loss was due to a decrease in losses recognized from MediBeacon as none were recognized during the six months ended June 30, 2026. Refer to Loss from equity investees in the Results of Operations section above for more information. Refer to Note 7. Investments to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information on our equity investments.
Non-GAAP Financial Measures and Other Information
Adjusted EBITDA
Adjusted EBITDA is not a measurement recognized under U.S. GAAP. In addition, other companies may define Adjusted EBITDA differently than we do, which could limit its usefulness.
Management believes that Adjusted EBITDA provides investors with meaningful information for gaining an understanding of our results as it is frequently used by the financial community to provide insight into an organization’s operating trends and facilitates comparisons between peer companies, since interest, taxes, depreciation, amortization and the other items listed in the definition of Adjusted EBITDA below can differ greatly between organizations as a result of differing capital structures and tax strategies. Adjusted EBITDA can also be a useful measure of a company’s ability to service debt. While management believes that non-U.S. GAAP measurements are useful supplemental information, such adjusted results are not intended to replace our U.S. GAAP financial results. Using Adjusted EBITDA as a performance measure has inherent limitations as an analytical tool as compared to net income (loss) or other U.S. GAAP financial measures, as this non-U.S. GAAP measure excludes certain items, including items that are recurring in nature, which may be meaningful to investors. As a result of the exclusions, Adjusted EBITDA should not be considered in isolation and does not purport to be an alternative to net income (loss) or other U.S. GAAP financial measures as a measure of our operating performance.
The calculation of Adjusted EBITDA, as defined by us, consists of Net income (loss) attributable to INNOVATE Corp., excluding: discontinued operations, if applicable; depreciation and amortization; other operating (income) loss (which is inclusive of (gain) loss on sale or disposal of assets, lease termination costs, (gains) losses on lease modifications, and asset impairment expense); interest expense; (gain) loss on extinguishment of debt; other (income) expense, net; income tax expense (benefit); non-controlling interests; share-based compensation expense; realignment and exit costs; facility commissioning costs; debt refinancing costs; and acquisition and disposition costs.
Adjusted EBITDA by segment is summarized as follows:
| (in millions): | Three Months Ended June 30, 2026 | 2025 | Increase / (Decrease) | Six Months Ended June 30, 2026 | 2025 | Increase / (Decrease) |
|---|---|---|---|---|---|---|
| Infrastructure | $48.7 | $19.3 | $29.4 | $71.7 | $36.0 | $35.7 |
| Life Sciences | (0.8) | (2.6) | 1.8 | (2.8) | (11.3) | 8.5 |
| Spectrum | 0.4 | 1.0 | (0.6) | 1.1 | 2.4 | (1.3) |
| Non-Operating Corporate | (2.0) | (2.0) | — | (4.0) | (4.2) | 0.2 |
| Other and Eliminations | — | — | — | — | — | — |
| Adjusted EBITDA | $46.3 | $15.7 | $30.6 | $66.0 | $22.9 | $43.1 |
The tables below provide reconciliations of net income (loss) attributable to INNOVATE Corp. to Adjusted EBITDA for the three months ended June 30, 2026 and 2025:
(in millions)
| Three Months Ended June 30, 2026 Infrastructure | Life Sciences | Spectrum | Non-Operating Corporate | Other and Eliminations | INNOVATE | |
|---|---|---|---|---|---|---|
| Net income (loss) attributable to INNOVATE Corp. | $26.4 | $(2.3) | $8.4 | $(21.8) | $— | $10.7 |
| Adjustments to reconcile net income (loss) to Adjusted EBITDA: | ||||||
| Depreciation and amortization | 2.8 | — | 0.7 | — | — | 3.5 |
| Depreciation and amortization (included in cost of revenue) | 3.5 | — | — | — | — | 3.5 |
| Interest expense | 1.4 | 2.1 | 6.8 | 17.3 | — | 27.6 |
| Gain on extinguishment of debt | — | — | (18.4) | — | — | (18.4) |
| Other (income) expense, net | (1.8) | — | 1.9 | (0.3) | — | (0.2) |
| Income tax expense | 11.1 | — | — | 2.0 | — | 13.1 |
| Non-controlling interests | 2.5 | (0.6) | (0.2) | — | — | 1.7 |
| Share-based compensation expense | — | — | — | 0.4 | — | 0.4 |
| Realignment and exit costs | 0.2 | — | — | — | — | 0.2 |
| Facility commissioning costs | 2.4 | — | — | — | — | 2.4 |
| Debt refinancing costs | — | — | — | 0.2 | — | 0.2 |
| Acquisition and disposition costs | 0.2 | — | 1.2 | 0.2 | — | 1.6 |
| Adjusted EBITDA | $48.7 | $(0.8) | $0.4 | $(2.0) | $— | $46.3 |
(in millions)
| Three Months Ended June 30, 2025 Infrastructure | Life Sciences | Spectrum | Non-Operating Corporate | Other and Eliminations | INNOVATE | |
|---|---|---|---|---|---|---|
| Net income (loss) attributable to INNOVATE Corp. | $5.5 | $(6.5) | $(6.1) | $(12.7) | $— | $(19.8) |
| Adjustments to reconcile net income (loss) to Adjusted EBITDA: | ||||||
| Depreciation and amortization | 3.1 | 0.1 | 1.2 | — | — | 4.4 |
| Depreciation and amortization (included in cost of revenue) | 3.0 | — | — | — | — | 3.0 |
| Other operating loss | 1.2 | — | — | — | — | 1.2 |
| Interest expense | 2.4 | 5.2 | 3.9 | 9.9 | — | 21.4 |
| Loss on extinguishment of debt | 0.3 | — | — | — | — | 0.3 |
| Other (income) expense, net | (0.3) | — | 2.3 | (2.0) | — | — |
| Income tax expense | 2.1 | — | — | 2.1 | — | 4.2 |
| Non-controlling interests | 0.6 | (1.4) | (0.4) | — | — | (1.2) |
| Share-based compensation expense | — | — | — | 0.7 | — | 0.7 |
| Realignment and exit costs | 1.4 | — | 0.1 | — | — | 1.5 |
| Adjusted EBITDA | $19.3 | $(2.6) | $1.0 | $(2.0) | $— | $15.7 |
52
Infrastructure: Net income from our Infrastructure segment for the three months ended June 30, 2026, increased $20.9 million to $26.4 million from $5.5 million for the three months ended June 30, 2025. Adjusted EBITDA from our Infrastructure segment for the three months ended June 30, 2026, increased $29.4 million to $48.7 million from $19.3 million for the three months ended June 30, 2025. The increase in Adjusted EBITDA was primarily driven by an increase in revenue and gross profit at DBMG's commercial structural steel fabrication and erection business, which had increased activity subsequent to the comparable period on certain large construction projects, combined with changes in the estimate of the cost to complete those projects recognized in the ordinary course driven by efficiencies recognized around certain projects, and, to a lesser extent, by an increase in revenue and gross profit at the construction modeling and detailing business. The increase was partially offset by an increase in recurring SG&A expenses, primarily driven by the timing of compensation-related expenses and a decrease in revenue and gross profit at our industrial maintenance and repair business due to timing of certain large construction projects in the comparable period that have since been completed.
Life Sciences: Net loss from our Life Sciences segment for the three months ended June 30, 2026, decreased $4.2 million to $2.3 million from $6.5 million for the three months ended June 30, 2025. Adjusted EBITDA loss from our Life Sciences segment for the three months ended June 30, 2026, decreased $1.8 million to $0.8 million from $2.6 million for the three months ended June 30, 2025. The decrease in Adjusted EBITDA loss was primarily driven by decreases in compensation-related expenses at R2 Technologies and Pansend.
Spectrum: Net income from our Spectrum segment for the three months ended June 30, 2026, increased $14.5 million to income of $8.4 million from a loss of $6.1 million for the three months ended June 30, 2025. Adjusted EBITDA from our Spectrum segment for the three months ended June 30, 2026, decreased $0.6 million to $0.4 million from $1.0 million for the three months ended June 30, 2025. The decrease in Adjusted EBITDA was primarily driven by the net decrease in revenue (as discussed in the Revenue section above) and an increase in cost of revenue.
Non-Operating Corporate: Net loss from our Non-Operating Corporate segment for the three months ended June 30, 2026, increased $9.1 million to $21.8 million from $12.7 million for the three months ended June 30, 2025. Adjusted EBITDA loss from our Non-Operating Corporate segment for the three months ended June 30, 2026, remained consistent at $2.0 million as compared to the three months ended June 30, 2025.
The tables below provide reconciliations of net income (loss) attributable to INNOVATE Corp. to Adjusted EBITDA for the six months ended June 30, 2026 and 2025:
(in millions)
| Six Months Ended June 30, 2026 Infrastructure | Life Sciences | Spectrum | Non-Operating Corporate | Other and Eliminations | INNOVATE | |
|---|---|---|---|---|---|---|
| Net income (loss) attributable to INNOVATE Corp. | $35.7 | $(5.6) | $1.9 | $(38.1) | $— | $(6.1) |
| Adjustments to reconcile net income (loss) to Adjusted EBITDA: | ||||||
| Depreciation and amortization | 5.7 | 0.1 | 1.9 | — | — | 7.7 |
| Depreciation and amortization (included in cost of revenue) | 6.7 | — | — | — | — | 6.7 |
| Other operating income | — | — | (0.1) | — | — | (0.1) |
| Interest expense | 3.2 | 4.0 | 10.8 | 34.1 | — | 52.1 |
| Gain on extinguishment of debt | — | — | (18.4) | — | — | (18.4) |
| Other (income) expense, net | (1.9) | — | 4.4 | (3.0) | — | (0.5) |
| Income tax expense | 15.2 | — | — | 0.8 | — | 16.0 |
| Non-controlling interests | 3.4 | (1.4) | (0.6) | — | — | 1.4 |
| Share-based compensation expense | — | 0.1 | — | 0.9 | — | 1.0 |
| Realignment and exit costs | 0.5 | — | — | — | — | 0.5 |
| Facility commissioning costs | 3.0 | — | — | — | — | 3.0 |
| Debt refinancing costs | — | — | — | 0.2 | — | 0.2 |
| Acquisition and disposition costs | 0.2 | — | 1.2 | 1.1 | — | 2.5 |
| Adjusted EBITDA | $71.7 | $(2.8) | $1.1 | $(4.0) | $— | $66.0 |
53
(in millions)
| Six Months Ended June 30, 2025 Infrastructure | Life Sciences | Spectrum | Non-Operating Corporate | Other and Eliminations | INNOVATE | |
|---|---|---|---|---|---|---|
| Net income (loss) attributable to INNOVATE Corp. | $10.1 | $(14.1) | $(11.5) | $(28.8) | $— | $(44.3) |
| Adjustments to reconcile net income (loss) to Adjusted EBITDA: | ||||||
| Depreciation and amortization | 6.2 | 0.2 | 2.4 | — | — | 8.8 |
| Depreciation and amortization (included in cost of revenue) | 6.5 | — | — | — | — | 6.5 |
| Other operating loss | 1.1 | — | — | — | — | 1.1 |
| Interest expense | 4.5 | 9.7 | 7.6 | 19.8 | — | 41.6 |
| Loss on extinguishment of debt | 0.3 | — | — | — | — | 0.3 |
| Other (income) expense, net | (0.6) | (4.5) | 4.5 | (3.4) | — | (4.0) |
| Income tax expense | 4.4 | — | — | 6.9 | — | 11.3 |
| Non-controlling interests | 1.0 | (2.8) | (0.7) | — | — | (2.5) |
| Share-based compensation expense | — | 0.2 | — | 1.3 | — | 1.5 |
| Realignment and exit costs | 2.5 | — | 0.1 | — | — | 2.6 |
| Adjusted EBITDA | $36.0 | $(11.3) | $2.4 | $(4.2) | $— | $22.9 |
Infrastructure: Net income from our Infrastructure segment for the six months ended June 30, 2026, increased $25.6 million to $35.7 million from $10.1 million for the six months ended June 30, 2025. Adjusted EBITDA from our Infrastructure segment for the six months ended June 30, 2026, increased $35.7 million to $71.7 million from $36.0 million for the six months ended June 30, 2025. The increase in Adjusted EBITDA was primarily driven by an increase in revenue and gross profit at DBMG's commercial structural steel fabrication and erection business, which had increased activity subsequent to the comparable period on certain large construction projects, combined with changes in the estimate of the cost to complete those projects recognized in the ordinary course driven by efficiencies recognized around certain projects, and, to a lesser extent, by an increase in revenue and gross profit at the construction modeling and detailing business. The increase was partially offset by a decrease in revenue and gross profit at our industrial maintenance and repair business due to timing of certain large construction projects in the comparable period that have since been completed and an increase in recurring SG&A expenses, primarily driven by the timing of compensation-related expenses.
Life Sciences: Net loss from our Life Sciences segment for the six months ended June 30, 2026, decreased $8.5 million to $5.6 million from $14.1 million for the six months ended June 30, 2025. Adjusted EBITDA loss from our Life Sciences segment for the six months ended June 30, 2026, decreased $8.5 million to $2.8 million from $11.3 million for the six months ended June 30, 2025. The decrease in Adjusted EBITDA loss was primarily due to a decrease in equity method losses recognized from MediBeacon, as discussed in the Loss from Equity Investees section above, and a decrease in SG&A expenses, primarily driven by decreases in compensation-related expenses at R2 Technologies and Pansend. These decreases were partially offset by a decrease in gross profit at R2 Technologies, driven by the decrease in revenue (as discussed in the Revenue section above).
Spectrum: Net income from our Spectrum segment for the six months ended June 30, 2026, increased $13.4 million to $1.9 million from a loss of $11.5 million for the six months ended June 30, 2025. Adjusted EBITDA from our Spectrum segment for the six months ended June 30, 2026, decreased $1.3 million to $1.1 million from $2.4 million for the six months ended June 30, 2025. The decrease in Adjusted EBITDA was primarily driven by the net decrease in revenue (as discussed in the Revenue section above) and an increase in cost of revenue.
Non-Operating Corporate: Net loss from our Non-Operating Corporate segment for the six months ended June 30, 2026, increased $9.3 million to $38.1 million from $28.8 million for the six months ended June 30, 2025. Adjusted EBITDA loss from our Non-Operating Corporate segment for the six months ended June 30, 2026, decreased slightly by $0.2 million to $4.0 million from $4.2 million for the six months ended June 30, 2025.
Backlog
Backlog is our estimate of the U.S. dollar amount of future revenues we expect to realize as a result of performing work on projects in backlog. Projects in backlog consist of awarded contracts, letters of intent, notices to proceed, change orders, and purchase orders obtained. Backlog increases as contract commitments are obtained, decreases as revenues are recognized and increases or decreases to reflect modifications in the work to be performed under the contracts. Backlog is converted to sales in future periods as work is performed or projects are completed. Backlog can be significantly affected by the receipt or loss of individual contracts.
Infrastructure
As of June 30, 2026, DBMG's backlog was $1,901.0 million, consisting of $1,810.2 million under contracts or purchase orders and $90.8 million under letters of intent or notices to proceed. Approximately $1,137.4 million, representing 59.8% of DBMG’s backlog as of June 30, 2026, was attributable to five contracts, letters of intent, notices to proceed or purchase orders. If one or more of these projects terminate or reduce their scope, DBMG’s backlog could decrease substantially. DBMG's backlog may, from time to time, include additional backlog amounts that are not included in the remaining unsatisfied performance obligations disclosed in Note 4. Revenue and Contracts in Process. This additional backlog may include commitments under master service agreements that are estimated amounts of work to be performed based on customer communications, historic performance and knowledge of our customers' intentions.
Liquidity and Capital Resources
Indebtedness
Non-Operating Corporate
10.50% Senior Secured Notes due 2027
In August 2025, we closed on an exchange offer and consent solicitation to eligible holders of our 8.50% senior secured notes due 2026 ("8.50% 2026 Senior Secured Notes") to exchange such notes for newly issued 10.50% senior secured notes due 2027 (the “10.50% 2027 Senior Secured Notes”). The Company, the guarantors party thereto from time to time and U.S. Bank Trust Company, National Association, as trustee (in such capacity, the “10.50% 2027 Senior Secured Notes Trustee”) and collateral trustee, entered into an indenture (the “10.50% 2027 Senior Secured Notes Indenture”) governing the 10.50% 2027 Senior Secured Notes and we issued $360.4 million aggregate principal amount of 10.50% 2027 Senior Secured Notes as consideration for the exchange of $328.1 million aggregate principal amount of the 8.50% 2026 Senior Secured Notes. The new principal amount includes fees payable to the lenders and $52.50 principal amount of 10.50% 2027 Senior Secured Notes per $1,000 principal amount of 8.50% 2026 Senior Secured Notes exchanged, paid to exchanging holders in lieu of the interest payment in respect of the 8.50% 2026 Senior Secured Notes that was due on August 1, 2025. The 10.50% 2027 Senior Secured Notes mature on February 1, 2027. Total fees and additional interest of $18.3 million payable to the lenders and capitalized into the new principal amount under the exchange offer was recorded as an OID and remaining unamortized deferred financing fees of $1.3 million allocated from the 8.50% 2026 Senior Secured Notes exchanged will be amortized into interest expense over the term of the notes using the effective interest rate method.
The 10.50% 2027 Senior Secured Notes accrue interest at a rate of 10.50% per year, payable semi-annually on February 1st and August 1st of each year, commencing on February 1, 2026. Total interest of $18.9 million, incurred from August 4, 2025 through January 31, 2026, was paid in kind and capitalized into the principal balance for the February 1, 2026 payment.
Pursuant to a July 31, 2026 supplemental indenture, interest due on August 1, 2026 on notes held by consenting holders was paid in kind, and those holders received additional notes as a 1.5% consent fee. Notes held by non-consenting holders remained subject to the existing cash interest payment requirements. Refer to Note 22. Subsequent Events to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information.
Aggregate interest expense for the new 10.50% 2027 Senior Secured Notes, including the contractual interest coupon and amortization of fees was $13.3 million and $26.3 million for the three and six months ended June 30, 2026, respectively.
As of June 30, 2026, the total carrying amount related to the notes was $371.0 million, inclusive of $379.3 million aggregate principal outstanding (which includes capitalized interest), partially offset by $7.7 million of the unamortized OID and $0.6 million of unamortized deferred financing fees. The effective interest rate on the 10.50% 2027 Senior Secured Notes was 14.4% as of June 30, 2026.
Our obligations under the 10.50% 2027 Senior Secured Notes Indenture are irrevocably and unconditionally guaranteed, jointly and severally, by the same guarantors that guarantee the 8.50% 2026 Senior Secured Notes (the “Subsidiary Guarantors”). The 10.50% 2027 Senior Secured Notes and the related guarantees are senior secured obligations for us and the Subsidiary Guarantors. The 10.50% 2027 Senior Secured Notes have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state securities laws and may not be offered or sold in the United States absent an effective registration statement or an applicable exemption from the registration requirements of the Securities Act.
If we complete certain asset sales (an "Asset Sale"), the terms of the 10.50% 2027 Senior Secured Notes Indenture may require us, in certain circumstances, to make an offer to purchase the 10.50% 2027 Senior Secured Notes with the net cash proceeds from such an Asset Sale at a price in cash equal to 101% of the principal amount thereof, together with accrued and unpaid interest, if any, to the date of purchase. For transactions constituting a Change of Control, we will be required to make an offer to purchase the 10.50% 2027 Senior Secured Notes for cash at a price equal to 101% of their aggregate principal amount on the date of purchase, plus any accrued and unpaid interest to the date of repurchase.
The 10.50% 2027 Senior Secured Notes Indenture contains covenants limiting, among other things, our ability, and, in certain cases, our subsidiaries, to incur additional indebtedness; create liens; pay dividends or make distributions in respect of capital stock; make certain restricted payments; sell assets; engage in certain transactions with affiliates; or consolidate or merge with, or sell substantially all of its assets to, another person. Additionally, the 10.50% 2027 Senior Secured Notes Indenture required us to meet certain milestones with respect to strategic alternatives for our operating subsidiaries, including asset sales generating at least $150 million in net proceeds, to be applied to the 10.50% 2027 Senior Secured Notes, such that by September 1, 2025 the Company needed to have a bona fide bid or term sheet related to a potential sale. The September 1, 2025 milestone was not reached, and in accordance with the indenture, we were thus required to commence a sales process for DBMG. The sales process for DBMG, which has been initiated and is proceeding, has separate milestone requirements, which we had either met or extended as of June 30, 2026, and we were in compliance with the milestone covenants requirements. The June 1, 2026 milestone for an executed purchase agreement was extended to August 28, 2026 and the Company is in compliance with the milestone covenants requirements as of the date of the filing of this Quarterly Report on Form 10-Q.
The 10.50% 2027 Senior Secured Notes Indenture contains customary events of default which could, subject to certain conditions, cause the 10.50% 2027 Senior Secured Notes to become immediately due and payable, including, but not limited to defaults by us in the payment of the principal of any of the 10.50% 2027 Senior Secured Notes when the same becomes due and payable at maturity, upon acceleration or redemption, or otherwise (other than pursuant to an offer to purchase by the Company) or in the payment of interest on any note when the same becomes due and payable, and the default continues for a period of 30 days; failure to comply with certain other covenants in the 10.50% 2027 Senior Secured Notes Indenture for a period of 60 days following notice by the 10.50% 2027 Senior Secured Notes Trustee or the holders of at least 30% in aggregate principal amount of the 10.50% 2027 Senior Secured Notes then outstanding; failure to pay or otherwise default on material debt; or failure to pay final judgments entered by a court or courts of competent jurisdiction aggregating $20 million or more (excluding amounts covered by insurance), which judgments are not paid, discharged or stayed, for a period of 60 days; certain events of bankruptcy or insolvency; and failure to comply with the milestone covenant described above.
In connection with the Spectrum agreements entered into on May 29, 2026 (refer to Note 3. Assets and Liabilities Held for Sale to the Condensed Consolidated Financial Statements), the Company, certain subsidiary guarantors, and U.S. Bank Trust Company, National Association, as trustee (in such capacity, the “Trustee”) and notes collateral agent (in such capacity, the “Collateral Agent”), entered into an amended supplemental indenture (the “Amended 10.50% 2027 Senior Secured Notes Supplemental Indenture”) to the 10.50% 2027 Senior Secured Notes Indenture. Pursuant to the Amended 10.50% 2027 Senior Secured Notes Supplemental Indenture, certain provisions of the 10.50% 2027 Senior Secured Notes Indenture, including certain definitions and negative covenants, were amended with the consent of the holders of at least a majority in aggregate principal amount of the Notes outstanding voting as a single class (the “Requisite Holders”). In addition, the Requisite Holders consented to the transactions related to the Spectrum Merger and the New Loan Agreement and waived any and all defaults, events of default or other defaults that may have occurred, or that may arise under the Indentures as a result thereof.
8.50% Senior Secured Notes due 2026
The original $330.0 million aggregate principal amount of 8.50% senior secured notes due February 1, 2026 (the "8.50% 2026 Senior Secured Notes") were issued in 2021 at 100% of par. In August 2025, we exchanged $328.1 million aggregate principal amount of the 8.50% 2026 Senior Secured Notes for new 10.50% 2027 Senior Secured Notes, as discussed above. Subsequent to the exchange, we had $1.9 million aggregate principal amount of the 8.50% 2026 Senior Secured Notes remaining. On February 2, 2026, the Company repaid the remaining principal balance and all accrued interest.
The 2026 Senior Secured Notes had a stated annual interest rate of 8.50% and had an effective interest rate of 9.3%, which reflected the initial $10.8 million of deferred financing fees in 2021, including underwriting fees. Interest was payable semi-annually in arrears on February 1st and August 1st of each year.
2027 Convertible Notes
On August 4, 2025, we exchanged $48.7 million of the then outstanding aggregate principal amount of the 2026 Convertible Notes for $53.5 million aggregate principal amount of newly issued 9.5% Convertible Senior Secured Notes due 2027 (the “2027 Convertible Notes”). The new principal amount included fees payable to the lenders and $47.50 principal amount of 2027 Convertible Notes per $1,000 principal amount of 2026 Convertible Notes exchanged, paid to exchanging holders in lieu of the interest payment in respect of the 2026 Convertible Notes that was due on August 1, 2025. The 2027 Convertible Notes mature on March 1, 2027, unless earlier converted, redeemed or purchased.
The 2027 Convertible Notes will be convertible into cash, shares of our common stock, or a combination thereof, at the Company’s election, based on an initial conversion rate of 23.6327 shares of common stock per $1,000 principal amount of 2027 Convertible Notes (equivalent to an initial conversion price of approximately $42.31 per share of our common stock), at any time prior to the close of business on the business day immediately preceding the maturity date, in principal amounts of $1,000 or an integral multiple of $1.00 in excess thereof. In addition, following a Make-Whole Fundamental Change (as defined in the 2027 Convertible Notes Indenture) or our delivery of a notice of redemption for the 2027 Convertible Notes, we will, in certain circumstances, be required to increase the conversion rate for a holder who elects to convert its 2027 Convertible Notes in connection with (i) such Make-Whole Fundamental Change or (ii) such notice of redemption.
The initial maximum number of securities underlying the 2027 Convertible Notes, assuming the largest “make-whole” addition to the conversion rate under the 2027 Convertible Notes Indenture, and assuming that we have obtained the requisite stockholder approval referred to above, was 1,543,174 shares of our common stock.
As of June 30, 2026, each $1,000 of principal of the 2027 Convertible Notes is convertible into 23.6327 shares of our common stock, for a total of 1,323,315 shares of common stock, which is equivalent to a conversion price of approximately $42.31 per share, as adjusted for the reverse stock split in 2024 and subject to further adjustment upon the occurrence of specified events. Based on the closing price of our common stock on June 30, 2026, the if-converted value of the 2027 Convertible Notes did not exceed its principal value.
The 2027 Convertible Notes accrue interest at a rate of 9.5% per year. Interest on the 2027 Convertible Notes is paid semi-annually on February 1st and August 1st of each year, commencing on February 1, 2026. Total interest of $2.5 million, incurred from August 4, 2025 through January 31, 2026, was paid in kind and capitalized into the principal balance for the February 1, 2026 payment. Subsequent to quarter end, pursuant to a July 31, 2026 supplemental indenture, interest due on August 1, 2026 on notes held by consenting holders was paid in kind, and those holders received additional notes as a 1.50% consent fee. Notes held by non-consenting holders remained subject to the existing cash interest payment requirements. Refer to Note 22. Subsequent Events to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information.
Aggregate interest expense, including the contractual interest coupon and amortization was $1.5 million and $3.0 million for the three and six months ended June 30, 2026, respectively.
The following amounts were recorded as an OID or deferred financing cost and are being amortized into interest expense over the term of the new 2027 Convertible Notes using the effective interest rate method: total new fees and additional interest of $2.9 million payable to the lenders and capitalized into the principal amount for the convertible notes exchanged, remaining unamortized deferred financing fees of $0.2 million allocated from the 2026 Convertible Notes exchanged, and a discount of $0.5 million, attributable to the increase in fair value of the embedded conversion option, offset partially by $2.4 million in remaining unamortized premiums allocated from the 2026 Convertible Notes exchanged. The effective interest rate on the 2027 Convertible Notes is 11.1%.
As of June 30, 2026, the total carrying amount related to the note was $55.4 million, inclusive of $56.0 million aggregate principal outstanding (which includes capitalized interest), partially offset by a remaining unamortized net OID of $0.5 million and unamortized deferred financing fees of $0.1 million.
The Company, the guarantors party thereto from time to time and U.S. Bank Trust Company, National Association, as trustee (in such capacity, the “2027 Convertible Notes Trustee”) and collateral trustee, entered into an indenture (the “2027 Convertible Notes Indenture”), dated as of August 4, 2025, governing the 2027 Convertible Notes. If we complete certain asset sales, the 2027 Convertible Notes Indenture may require us in certain circumstances to make an offer to purchase the 2027 Convertible Notes with the net cash proceeds from such an asset sale at a price in cash equal to 101% of the principal amount thereof, together with accrued and unpaid interest, if any, to the date of purchase. Additionally, if we undergo a Fundamental Change, subject to certain conditions, we may be required to purchase all or any portion of the 2027 Convertible Notes for cash at 100% of the principal amount to be purchased, plus accrued and unpaid interest, including additional interest, if any, to, but excluding, the applicable purchase date. The Fundamental Change definition excludes ownership of our equity by Lancer Capital LLC and its affiliates.
The 2027 Convertible Notes Indenture contains covenants limiting, among other things, our ability and, in certain cases, our subsidiaries, to incur additional indebtedness; create liens; pay dividends or make distributions in respect of capital stock; make certain restricted payments; sell assets; engage in certain transactions with affiliates; or consolidate or merge with, or sell substantially all of its assets to, another person. These covenants are subject to a number of important exceptions and qualifications.
The 2027 Convertible Notes Indenture contains customary events of default, including cross-default provisions with other INNOVATE debt instruments, which could, subject to certain conditions, cause the 2027 Convertible Notes to become immediately due and payable, including, but not limited to defaults by us in the payment of the principal of any of the 2027 Convertible Notes when the same becomes due and payable at maturity, upon acceleration or redemption, or otherwise or in the payment of interest on any note when the same becomes due and payable, and the default continues for a period of 30 days; failure to comply with certain other covenants in the 2027 Convertible Notes Indenture for a period of 60 days following notice by the 2027 Convertible Notes Trustee or the holders of at least 25% in aggregate principal amount of the 2027 Convertible Notes then outstanding; failure to pay or otherwise default on material debt; or failure to pay final judgments entered by a court or courts of competent jurisdiction aggregating $20 million or more (excluding amounts covered by insurance), which judgments are not paid, discharged or stayed, for a period of 60 days; and certain events of bankruptcy or insolvency.
In connection with the Spectrum agreements entered into on May 29, 2026 (refer to Note 3. Assets and Liabilities Held for Sale to the Condensed Consolidated Financial Statements), the Company, certain subsidiary guarantors, and U.S. Bank Trust Company, National Association, as trustee (in such capacity, the “Trustee”) and notes collateral agent (in such capacity, the “2027 Convertible Notes Collateral Agent”), entered into an amended supplemental indenture (the “Amended 2027 Convertible Notes Supplemental Indenture”) to the 2027 Convertible Notes Indenture. Pursuant to the Amended 2027 Convertible Notes Supplemental Indenture, certain provisions of the 2027 Convertible Notes Indenture, including certain definitions and negative covenants, were amended with the consent of the holders of at least a majority in aggregate principal amount of the notes outstanding voting as a single class (the “2027 Convertible Notes Requisite Holders”). In addition, the 2027 Convertible Notes Requisite Holders consented to the transactions related to the Spectrum Merger and the New Loan Agreement and waived any and all defaults, events of default or other defaults that may have occurred, or that may arise under the Indentures as a result thereof.
2026 Convertible Notes
The original 7.50% convertible notes (the "2026 Convertible Notes") were issued under an indenture dated February 1, 2021, between us and U.S. Bank, as trustee. As discussed above, on August 4, 2025, pursuant to the Exchange Agreements, we exchanged $48.7 million aggregate principal amount of the 2026 Convertible Notes for new 2027 Convertible Notes. Subsequent to the exchanges and, as of June 30, 2026, we had $0.2 million aggregate principal remaining of the 2026 Convertible Notes. As of June 30, 2026, the remaining 2026 Convertible Notes had a net carrying value of $0.2 million. The effective interest rate on the remaining 2026 Convertible Notes as of June 30, 2026 was 3.0%.
The 2026 Convertible Notes matured on August 1, 2026, together with all outstanding interest and were redeemed on August 3, 2026. Refer to Note 22. Subsequent Events to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference.
Revolving Line of Credit
We have a revolving credit agreement with MSD PCOF Partners IX, LLC ("MSD"), which has a maximum commitment of $20.0 million ("Revolving Line of Credit"). As of June 30, 2026, the outstanding balance was $20.0 million. The maturity date of the Revolving Line of Credit, as amended on August 4, 2025, is September 15, 2026. The Revolving Line of Credit has an interest rate margin applicable to loans borrowed under the Revolving Line of Credit of 5.75%, and the benchmark rates for the interest are SOFR-based rates. As of June 30, 2026, the interest rate on the Revolving Line of Credit was 9.7%. Interest is paid quarterly in arrears. The Revolving Line of Credit also includes a commitment fee at a per annum rate of 1.0% calculated based on the actual daily amount of unused availability under the Revolving Line of Credit with MSD, and also includes a requirement for prepayment using the net cash proceeds received from certain asset sales. The affirmative and negative covenants governing the Revolving Line of Credit are substantially consistent with the affirmative and negative covenants contained in the indentures that govern our senior secured notes.
On August 4, 2025, INNOVATE and MSD entered into an Eighth Amendment to Credit Agreement, which among other things, extended the maturity of the 2020 Revolving Credit Agreement to September 15, 2026, and added a new $0.4 million extension fee that is payable on the earlier of maturity date or date of prepayment of the debt. The $0.4 million extension fee and third-party legal costs of $0.3 million incurred under the amendment are being amortized into interest expense over the term of the Revolving Line of Credit.
Any failure to comply with the restrictions in the agreements governing our indentures, or any agreement governing other indebtedness we could incur, may result in an event of default under those agreements. Such default may allow the creditors to accelerate the related debt, which acceleration may trigger cross-acceleration or cross-default provisions in other debt.
In connection with the Spectrum agreements entered into on May 29, 2026, we entered into a ninth amendment (the “Ninth Amendment”) to the Credit Agreement with MSD. Pursuant to the Ninth Amendment, certain provisions of the MSD Credit Agreement, including certain definitions and negative covenants, were amended with the consent of MSD. In addition, MSD consented to the transactions related to the Spectrum Merger and the New Loan Agreement and waived any and all defaults, events of default or other defaults that may have occurred, or that may arise under the MSD Credit Agreement as a result thereof.
CGIC Promissory Note
On August 4, 2025, the Company and CGIC entered into a Subordinated Secured Promissory Note to, among other things, extend the maturity of our existing subordinated unsecured promissory note with CGIC (the “CGIC Note”) from February 28, 2026 to April 30, 2027, and secure the amended CGIC Note by a third priority lien on the same collateral securing the 10.50% 2027 Senior Secured Notes and the 2027 Convertible Notes. The amended CGIC Note has an interest rate of 16.0%, and an effective interest rate of 14.6% as of June 30, 2026. Interest on the amended CGIC Note will be paid monthly and in kind through August 31, 2026. All interest payments thereafter will be payable in cash, in arrears. As part of the agreement with CGIC, the accrued value of 8,063 shares of Series A-4 Preferred Stock of the Company held by CGIC, and unpaid accrued dividends for the A-3 and A-4 Preferred Stock were exchanged for an additional principal amount of the CGIC Note, on a dollar-for-dollar basis (the “Preferred Stock Exchange”). The additional principal amount incurred under the Preferred Stock Exchange was $9.6 million (reflective of the $9.1 million accrued value of the Series A-4 Preferred Stock and $0.5 million in accrued dividends on the Series A-3 and A-4 Preferred Stock). In addition, an extension fee and accrued interest of $2.4 million on the CGIC Note through July 31, 2025, were capitalized to the new principal amount of the CGIC Note, for a total new aggregate outstanding principal amount of $43.0 million. The new extension fee was recorded as an OID to the carrying amount of the note and is being amortized into interest expense over the term of the CGIC Note using the effective interest rate method.
The original CGIC subordinated unsecured promissory note, which was issued at 100% of par entered into in 2023 in connection with the redemption of DBM Global Intermediate Holdco Inc.'s Series A Fixed-to-Floating Rate Perpetual Preferred Stock (the “DBMGi Series A Preferred Stock”), had a principal amount of $35.1 million original maturity date of February 28, 2026, and bore interest at 9.0% per annum through May 8, 2024, 16.0% per annum from May 9, 2024 to May 8, 2025, and 32.0% per annum thereafter.
For the three and six months ended June 30, 2026, interest expense recognized relating to the CGIC Note, including the contractual interest coupon and amortization of the discount, was $1.8 million and $3.5 million, respectively. During the six months ended June 30, 2026, in accordance with the terms of the amended CGIC Note, $3.8 million of interest was capitalized into the principal balance. As of June 30, 2026, the total carrying amount related to the note was $50.3 million, inclusive of $49.7 million of principal (including capitalized interest) and a net unamortized premium of $0.6 million.
The terms of the CGIC Note include a mandatory prepayment requirement which requires us to prepay the CGIC Note (together with all accrued and unpaid interest and all other amounts payable under the CGIC Note), after the indefeasible repayment and satisfaction in full in cash of all obligations under the 10.50% 2027 Senior Secured Notes, the 10.50% 2027 Senior Secured Notes Indenture, the 2027 Convertible Notes, the 2027 Convertible Notes Indenture and all other Senior Debt (or, in each case, under any refinancing indebtedness in respect thereof), upon the occurrence of an Asset Sale (as defined in the agreement), in an amount equal to the Net Cash Proceeds (as defined in the agreement) from such Asset Sale, with such prepayment due no later than two (2) Business Days after the receipt of such Net Cash Proceeds by us (or our subsidiary, if applicable) from such Asset Sale.
The note contains customary events of default and contains cross-default provisions with our other debt instruments which could, subject to certain conditions, cause the note to become immediately due and payable.
Infrastructure
On May 20, 2025, DBMG entered into an Amended and Restated Credit agreement (the "DBMG Credit Agreement"), with the lenders which are party thereto from time to time (each a “Lender” and collectively the “Lenders”) and UMB BANK, N.A. ("UMB"). The DBMG Credit Agreement provides DBMG with senior secured debt financing in an amount up to $220.0 million in the aggregate, consisting of (i) a senior secured revolving credit facility (the “DBMG Revolving Facility”) in an aggregate amount of $135.0 million and (ii) a senior secured term loan facility in the amount of $85.0 million. The DBMG Credit Agreement also contains an accordion feature to increase the allowable size of the DBMG Revolving Facility by an additional $50.0 million. The DBMG Revolving Facility and the term loan facility will mature on May 20, 2030. DBMG entered into the DBMG Credit Agreement to fully repay DBMG’s existing debt obligations and provide additional working capital capacity.
The term loan and borrowings under the DBMG Credit Agreement bear interest at a rate per annum equal to a SOFR Rate plus a variable spread based on a Senior Funded Indebtedness to EBITDA Ratio as defined in the agreement with an interest rate floor of 4.25% per annum. Interest is paid monthly on DBMG's revolving loans, and the effective interest rate on DBMG's revolving loans was 6.3% as of June 30, 2026. The DBMG Revolving Facility has an unused commitment fee of 0.50% per annum times the average daily unused availability under the line. Principal payments and interest on DBMG's term loan are paid monthly, and the effective interest rate was 6.9% as of June 30, 2026.
At the time of entering into the DBMG Credit Agreement, deferred financing fees totaling $1.8 million were capitalized as original issue discounts and included in the carrying amount of the debt in the Condensed Consolidated Balance Sheet and $0.1 million in fees paid to third parties were expensed. Capitalized fees are amortized over the remaining life of the debt under the effective interest rate method and are included in interest expense.
DBMG had availability for revolving loans of $129.2 million as of June 30, 2026.
The obligations of the Borrowers under the new DBMG Credit Agreement are guaranteed by certain domestic subsidiaries of DBMG. As security for the Borrowers’ obligations under the DBMG Credit Agreement, (i) DBMG and its domestic subsidiaries have granted a first priority lien on substantially all their tangible and intangible personal property, including, without limitation, accounts receivable, equipment and the equity interests of certain of DBMG’s direct and indirect subsidiaries, and (ii) certain of the domestic subsidiaries of DBMG have granted a first priority lien on ten parcels of real estate owned by such subsidiaries.
The DBMG Credit Agreement contains usual and customary restrictive and financial covenants related to debt levels and performance, including a Fixed Charge Coverage Ratio; and a Senior Funded Indebtedness to EBITDA Ratio, both as defined in the DBMG Credit Agreement. The DBMG Credit Agreement contains a Change in Control clause, which would constitute an Event of Default, both as defined in the DBMG Credit Agreement, which could accelerate the maturity of the DBMG debt in the future upon certain events, including a sale of DBMG. As the Change in Control clause has not been triggered, the DBMG debt instruments remain classified as non-current as of June 30, 2026, except amounts due within the next 12 months, as originally defined in the DBMG Credit Agreement.
DBMG is in compliance with its debt covenants as of June 30, 2026.
Life Sciences
On August 4, 2025, Lancer Capital LLC ("Lancer"), a related party, and R2 Technologies entered into an Amended and Restated Senior Secured Promissory Note (the "Lancer Note"), which was previously amended multiple times as further described below, and which, among other things, extended the maturity of the note to the earlier of August 1, 2026, or the occurrence of (i) a Change of Control (as defined in the amended note) or (ii) the sale of all or substantially all of the assets of R2 Technologies. The Lancer Note can be repaid at any time with an optional prepayment of the entire then-outstanding and unpaid principal and accrued interest upon five-days written notice to Lancer Capital. The Lancer Note has an interest rate of 12% and removed certain exit and default fees. Accrued and unpaid interest is capitalized monthly into the principal balance.
On July 31, 2026, the maturity of R2 Technologies' secured promissory note with Lancer was extended from August 1, 2026 to the earlier of December 31, 2026, or the occurrence of (i) a Change of Control (as defined in the amended note) or (ii) the sale of all or substantially all of the assets of R2 Technologies.
The total initial principal amount of the amended Lancer Note on August 4, 2025 was $43.5 million, which incorporated the $20.0 million principal amount of the note as previously amended effective January 31, 2024 (which was comprised of a principal amount of $17.4 million and unpaid accrued interest of $2.6 million), accrued interest of $7.0 million and $16.5 million in accrued exit fees which had been incurred from January 31, 2024 through August 4, 2025. In addition, a new 5% extension fee of $2.2 million was capitalized into the principal amount on August 4, 2025 and is being amortized over the term of the note using the effective interest rate method and is included in interest expense.
As of June 30, 2026, the effective interest rate on the note, as amended, was 17.0%. Interest expense, including amortization of fees, related to the Lancer Note was $2.1 million and $4.1 million for the three months and six months ended June 30, 2026, respectively. For the six months ended June 30, 2026, in accordance with the 12% note agreement, $3.0 million of accrued interest, excluding exit fees and extension fees, was capitalized into the principal balance.
As of June 30, 2026, the total carrying amount relating to the note, which is included within the Current portion of debt obligations in the Condensed Consolidated Balance Sheet, was $50.7 million, inclusive of $50.9 million of principal (which includes capitalized interest and fees), partially offset by $0.2 million of the unamortized OID for the extension fee.
Spectrum (Held for Sale)
On August 4, 2025, Spectrum had entered into a Tenth Omnibus Amendment to Secured Notes and Limited Consent to MSD Secured Note and Intercreditor Agreement with the note holders of Spectrum's $69.7 million 8.50% and 11.45% Notes (the “Spectrum Notes”) to, among other things, extend the maturity of such notes from August 15, 2025 to September 30, 2026 (the “Spectrum Notes Extension”). In connection with the Spectrum Notes Extension in August 2025, we entered into the Spectrum Letter with the lenders, which required us to meet certain milestones with respect to strategic alternatives for the Spectrum segment, such that, if the Spectrum Notes were not repaid in full in cash on or before November 1, 2025, the Spectrum Letter provided that we were required to commence an alternative strategic process for HC2B which includes a sale of HC2B with the net proceeds to be applied to the Spectrum Notes. The November 1, 2025 milestone was not reached and in accordance with the Spectrum Letter, management initiated a strategic process for HC2B.
In connection with the Spectrum merger, on May 29, 2026, Broadcasting entered into a loan agreement (the “New Spectrum Loan Agreement”), as borrower, with Merger Sub, as lender, and HC2 Holdco and certain of Broadcasting’s subsidiaries, as guarantors. The New Spectrum Loan Agreement provides for a bridge loan facility in an aggregate principal amount of $105 million (the “Bridge Loan Facility”) which was funded on a single drawing on May 29, 2026. The proceeds of the Bridge Loan Facility were used to (a) fully satisfy and discharge all non-contingent obligations, including all accrued and unpaid interest and fees, under the Spectrum Notes, (b) repurchase equity interests in Broadcasting and DTV held by holders of the Spectrum Notes; and (c) to pay related transaction costs. As a result of these transactions and the Spectrum Merger agreement, the milestones associated with the Spectrum Letter were satisfied in full. Prior to repurchase, the lenders held 20,408 shares of common stock in HC2B, 2,222,222 shares of common stock in DTV, and warrants to purchase 145,825 shares of common stock of HC2B which could have been exercised at any time until August 31, 2028, at an exercise price of $0.01 per share. These redeemable equity interests in HC2B and DTV were repurchased at a nominal amount and were recorded against APIC. As a result of the repurchases of these redeemable non-controlling interests, our ownership in Broadcasting and DTV increased from 98.0% to 100.0% and from 69.2% to 76.5%, respectively.
The total carrying amount of the Spectrum Notes at the time of extinguishment was approximately $123.2 million, including accrued interest and exit fees of $56.8 million, and the total payoff amount was $104.8 million. As a result, a gain on extinguishment of debt $18.4 million was recognized and included within Gain (loss) on extinguishment of debt on the Condensed Consolidated Statement of Operations for the three and six months ended June 30, 2026. Additional related transaction costs of $2.8 million were capitalized to the new debt and are being amortized over the term of the new debt.
Loans under the Bridge Loan Facility (“Spectrum Loans”) will accrue interest at a rate per annum equal to 8.00%, payable quarterly in kind by capitalizing such interest as additional principal of the Spectrum Loans on each interest payment date. The Spectrum Loans mature on May 29, 2027; however, upon consummation of the Spectrum Merger, the Spectrum Loans (including all accrued and capitalized interest thereon) will be extinguished in full. Broadcasting may not voluntarily prepay the Spectrum Loans prior to maturity. The Spectrum Loans also include a yield protection premium clause, which specifies that in the event of any early repayment or acceleration of the Spectrum Loans, or the Spectrum Loans reaching maturity without the occurrence of the consummation of the Spectrum Merger, Broadcasting is required to repay in cash an amount sufficient to result in a minimum cash return on the original principal amount of the Spectrum Loans, including all accrued and capitalized interest thereon, at a ratio of 1.5 to 1.0. The yield protection premium is being amortized over the term of the Spectrum Loans. As of June 30, 2026, the effective interest rate on the Spectrum Loans was approximately 54.0% per annum.
The New Spectrum Loan Agreement contains certain affirmative and negative covenants that limit the ability of Broadcasting and the Guarantors, among other things, and subject to certain exceptions, to incur debt or liens, make investments, enter into certain mergers, consolidations, and acquisitions, and pay dividends and make other restricted payments. The New Spectrum Loan Agreement contains certain events of default, including relating to a change of control and termination of the Spectrum Merger Agreement.
Refer to Note 3. Assets and Liabilities Held for Sale to the Condensed Consolidated Financial Statements, which is incorporated by reference herein, for additional information.
Restrictive Covenants
Pursuant to the 8.50% 2026 Senior Secured Notes Supplemental Indenture executed in August 2025, substantially all of the restrictive covenants for the 8.50% 2026 Senior Secured Notes were eliminated.
The indenture governing the 2027 Senior Secured Notes dated August 4, 2025, by and among INNOVATE, the guarantors party thereto and U.S. Bank Trust Company, National Association, as trustee (in such capacity, the “10.50% 2027 Senior Secured Notes Trustee”) and collateral trustee (the "10.50% 2027 Senior Secured Notes Indenture"), contains certain affirmative and negative covenants limiting, among other things, the ability of the Company, and, in certain cases, the Company’s subsidiaries, to incur additional indebtedness; create liens; pay dividends or make distributions in respect of capital stock; make certain restricted payments; sell assets; engage in certain transactions with affiliates; or consolidate or merge with, or sell substantially all of its assets to, another person. Additionally, the 10.50% 2027 Senior Secured Notes Indenture required us to meet certain milestones with respect to strategic alternatives for our operating subsidiaries, including asset sales generating at least $150 million in net proceeds, to be applied to the 10.50% 2027 Senior Secured Notes, such that by September 1, 2025, we needed to have a bona fide bid or term sheet related to a potential sale. The September 1, 2025 milestone was not reached, and in accordance with the indenture, we were thus required to commence a sales process for DBMG. The sales process for DBMG, which had been initiated and is proceeding, has separate milestone requirements, which we have either met or extended as of June 30, 2026 and we were compliance with the milestone covenants requirements.
In connection with the Spectrum agreements entered into on May 29, 2026, INNOVATE, certain subsidiary guarantors, and U.S. Bank Trust Company, National Association, as trustee (in such capacity, the “Trustee”) and notes collateral agent (in such capacity, the “Collateral Agent”), entered into an amended supplemental indenture (the “Amended 10.50% 2027 Senior Secured Notes Supplemental Indenture”) to the 10.50% 2027 Senior Secured Notes Indenture. Pursuant to the 10.50% 2027 Senior Secured Notes Supplemental Indenture, certain provisions of the 10.50% 2027 Senior Secured Notes Indenture, including certain definitions and negative covenants, were amended with the consent of the holders of at least a majority in aggregate principal amount of the Notes outstanding voting as a single class (the “Requisite Holders”). In addition, the Requisite Holders consented to the transactions related to the Spectrum Merger and the New Loan Agreement and waived any and all defaults, events of default or other defaults that may have occurred, or that may arise under the Indentures as a result thereof.
In connection with the Spectrum Notes Extension in August 2025, we entered into the Spectrum Letter with the lenders, which required us to meet certain milestones with respect to strategic alternatives for the Spectrum segment, such that, if the Spectrum Notes were not repaid in full in cash on or before November 1, 2025, the Spectrum Letter provided that we were required to commence an alternative strategic process for HC2B which includes a sale of HC2B with the net proceeds to be applied to the Spectrum Notes. The November 1, 2025 milestone was not reached and in accordance with the Spectrum Letter, management initiated a strategic process for HC2B.
On May 29, 2026, Broadcasting closed on a refinancing transaction. In addition, Broadcasting and HC2 Holdco, subsidiaries of INNOVATE, entered into a definitive agreement pursuant to which INNOVATE will sell a controlling interest in Broadcasting to CONX, subject to the satisfaction of customary closing conditions, including the receipt of required regulatory approvals.
In connection with the Spectrum merger, on May 29, 2026, Broadcasting entered into a loan agreement (the “New Spectrum Loan Agreement”), as borrower, with Merger Sub, as lender, and HC2 Holdco and certain of Broadcasting’s subsidiaries, as guarantors. The New Spectrum Loan Agreement provides for the Bridge Loan Facility which was funded on a single drawing on May 29, 2026. The proceeds of the Bridge Loan Facility were used to (a) fully satisfy and discharge all non-contingent obligations, including all accrued and unpaid interest and fees, under the Spectrum Notes; (b) repurchase equity interests in Broadcasting and DTV held by holders of the Spectrum Notes; and (c) to pay related transaction costs. As a result of these transactions and the Spectrum Merger agreement, the milestones associated with the Spectrum Letter were satisfied in full.
The New Spectrum Loan Agreement contains certain affirmative and negative covenants that limit the ability of Broadcasting and the Guarantors, among other things, and subject to certain exceptions, to incur debt or liens, make investments, enter into certain mergers, consolidations, and acquisitions, and pay dividends and make other restricted payments. The New Loan Agreement contains certain events of default, including relating to a change of control and termination of the Merger Agreement.
The instruments governing the Company’s Series A-3 Preferred Stock and Series A-4 Preferred Stock also limit our and our subsidiaries ability to take certain actions, including, among other things, to incur additional indebtedness; issue additional Series A-3 Preferred Stock and Series A-4 Preferred Stock; engage in transactions with affiliates; and make certain restricted payments. These limitations are subject to a number of important exceptions and qualifications.
We have conducted our operations in a manner that has resulted in compliance with the indentures, and as of June 30, 2026, we are in compliance with the covenants of our debt agreements.
The debt instruments associated with our Infrastructure segment contain customary restrictive and financial covenants related to debt levels and performance, including a Fixed Charge Coverage Ratio covenant, and a Senior Funded Indebtedness to EBITDA Ratio, both as defined in the agreement. The debt instruments associated with our Infrastructure segment also contain a Change in Control clause, which would constitute an Event of Default, both as defined in the DBMG Credit Agreement, which could accelerate the maturity of the segment's debt in the future upon certain events, including a sale of DBMG. As the Change in Control clause has not been triggered, the DBMG debt instruments remain classified as non-current as of June 30, 2026, except amounts due within the next 12 months, as originally defined in the DBMG Credit Agreement.
As of June 30, 2026, our Infrastructure segment was in compliance with the covenants of its debt agreement.
Short- and Long-Term Liquidity Considerations and Risks
Our Non-Operating Corporate segment's liquidity needs have primarily been for interest payments on our senior secured notes, convertible notes, Revolving Line of Credit, CGIC Note, and dividend payments, out of legally available funds, on our Series A-3 and Series A-4 Preferred Stock and recurring operational expenses. As a result of our debt refinancing transactions in 2025 as discussed in "Indebtedness" above, certain interest payments for our Corporate debt will be or have been paid in kind and therefore will be incorporated into the respective principal balances to be paid on maturity or redemption of the respective debt.
On a consolidated continuing operations basis, and excluding our Spectrum segment, as of June 30, 2026, we had $87.8 million of cash and cash equivalents, excluding restricted cash, compared to $108.2 million as of December 31, 2025. On a stand-alone basis, as of June 30, 2026, our Non-Operating Corporate segment had cash and cash equivalents of $1.5 million, as compared to $4.2 million as of December 31, 2025.
Our subsidiaries' principal liquidity requirements arise from cash used in operating activities, debt service, and capital expenditures, including purchases of steel construction equipment and other equipment, development of back-office systems, operating costs and expenses, and income taxes.
As of June 30, 2026, we had $626.4 million of principal indebtedness on a consolidated continuing operations basis (excluding Spectrum debt) compared to $617.5 million as of December 31, 2025, a net increase of $8.9 million, due to increases in debt at our Non-Operating Corporate and Life Sciences segments, partially offset by a decrease in debt at our Infrastructure segment. The increase at our Non-Operating Corporate segment was due to the capitalization of an aggregate $25.2 million of accrued interest into the outstanding principal balances for our 10.50% 2027 Senior Secured Notes, 9.50% 2027 Convertible Notes and CGIC Note, partially offset by a $1.9 million principal payment for the redemption of the remaining 8.50% 2026 Senior Secured Notes that matured in 2026. The increase at our Life Sciences segment was due to the capitalization of fees and unpaid accrued interest of $3.0 million at R2 Technologies into the outstanding principal balance of their note with Lancer. These increases in debt were partially offset by a $17.4 million decrease in debt at our Infrastructure segment due to repayments on their credit facility and amortization payments on their term loan.
On a stand-alone basis, our Non-Operating Corporate segment principal indebtedness, all of which matures within the next twelve months, was $505.2 million and $481.9 million as of June 30, 2026 and December 31, 2025, respectively. The June 30, 2026 indebtedness balance consists of the $379.3 million aggregate principal amount of 10.50% 2027 Senior Secured Notes, $56.0 million aggregate principal amount of 9.50% 2027 Convertible Notes, $0.2 million aggregate principal amount remaining of 7.50% 2026 Convertible Notes, $49.7 million principal amount of the CGIC Note and $20.0 million aggregate principal amount drawn on our Revolving Line of Credit.
We have entered into agreements for the Spectrum Merger. If consummated, the Spectrum Merger would extinguish the Bridge Loan Facility.
Our Non-Operating Corporate segment is required to make semi-annual interest payments on the 10.50% 2027 Senior Secured Notes and on the 2027 Convertible Notes, on February 1st and August 1st of each year. For the first interest period, which was the interest period ending on January 31, 2026, interest was paid in kind. Subsequent to quarter end, interest due on August 1, 2026 on notes held by consenting holders was also paid in kind, and those holders received additional notes as a 1.5% consent fee. Notes held by non-consenting holders remained subject to the existing cash interest payment requirements. Interest payments on the CGIC Note are required monthly; however, interest will be paid in kind through August 31, 2026. All remaining interest payments will be paid in cash in arrears. We are also required to make quarterly interest payments on our Revolving Line of Credit and semi-annual interest payments on the 2026 Convertible Notes on February 1st and August 1st of each year.
We are required to make dividend payments, out of legally available funds, on our outstanding Series A-3 Preferred Stock and Series A-4 Preferred Stock on January 15th, April 15th, July 15th, and October 15th of each year. The Series A-3 Preferred Stock and Series A-4 Preferred Stock have a redemption date of July 1, 2026. On the maturity date, the holders were entitled to redeem, out of legally available funds, the Series A-3 Preferred Stock and Series A-4 Preferred Stock at the accrued value per share plus accrued but unpaid dividends (to the extent not included in the accrued value of Series A-3 and Series A-4); however, at this time the Company does not have legally available funds to complete the redemption.
On June 30, 2026, the holder of our outstanding Series A-3 and Series A-4 Preferred Stock delivered a redemption notice requiring the Company to redeem those shares at the redemption price (accrued value plus all accrued and unpaid dividends, to the extent not included in the accrued value). The Company did not have sufficient legally available funds to pay the redemption price in cash or other assets. Under the terms of the certificates of designation, because the preferred shares were not redeemed when required, they remain outstanding and continue to be entitled to all powers, designations, preferences, and other rights, including the right to accrual and payment of dividends and conversion rights.
The Series A-3 and Series A-4 Preferred Stock accrue a cumulative quarterly cash dividend at an annualized rate of 7.50%. The accrued values of the Series A-3 and Series A-4 Preferred Stock accrete quarterly at an annualized rate of 4.00% that is reduced to 2.00% or 0.0% if the Company achieves specified rates of growth measured by increases in its net asset value; provided, that the accreting dividend rate will be 7.25% in the event that (A) the daily volume weighted-average price ("VWAP") of the Company's common stock is less than a certain threshold amount, (B) the Company's common stock is not registered under Section 12(b) of the Securities Exchange Act of 1934, as amended, or (C) the Company's common stock is not listed on certain national securities exchanges or the Company is delinquent in the payment of any cash dividends.
During the first and second quarters of 2026, the Board did not declare any cash dividends with respect to INNOVATE’s issued and outstanding Series A-3 Preferred Stock and Series A-4 Preferred Stock. Aggregate quarterly dividends of $0.4 million and $0.3 million, respectively, for the first and second quarters of 2026, included the annual cash dividend of 7.5% per annum which was accrued and also the accreting dividend of 7.25% per annum. Refer to Note 16. Temporary Equity for additional information.
Our Non-Operating Corporate segment received $0.8 million in net tax sharing payments from our Infrastructure segment for the six months ended June 30, 2026. Additionally, our Non-Operating Corporate segment received $2.7 million and $7.3 million in dividends from our Infrastructure segment during the three and six months ended June 30, 2026, respectively. Subsequent to quarter end, on July 8, 2026, DBMG declared a $12.0 million cash dividend which was paid on August 3, 2026, of which our Non-Operating Corporate segment received $11.0 million.
We have financed our growth and operations to date, and expect to finance our future growth and operations, through public offerings and private placements of debt and equity securities, credit facilities, vendor financing, finance lease financing and other financing arrangements, as well as cash generated from the operations of our subsidiaries.
Going Concern
The accompanying unaudited Condensed Consolidated Financial Statements have been prepared assuming that the Company will continue as a going concern. However, as of the date of these financial statements, there is substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued.
The principal conditions leading to this conclusion are the upcoming maturities of the Company's debt obligations. Based on these conditions, we may not be able to meet our obligations at maturity nor comply with certain cross-default provisions under the 10.50% 2027 Senior Secured Notes over the next twelve months, or any potential breach of the milestone covenant of the 10.50% 2027 Senior Secured Notes Indenture which has required the Company to commence and proceed with a sales process for all or substantially all of DBMG's assets or equity interests in accordance with certain dates and deadlines. Refer to Note 12. Debt Obligations to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference.
Management has evaluated the significance of these conditions in relation to the Company's ability to meet its obligations. The potential inability to refinance or extend the maturity of the aforementioned current debt, or to obtain additional financing, raises substantial doubt about the Company's ability to continue as a going concern.
Management plans to alleviate these conditions through various initiatives it is currently exploring, including pursuing asset sales, potentially refinancing debt and raising additional capital. However, there can be no assurance that we will have the ability to be successful in any asset sales, additional capital raises, or the refinancing of our existing debt, on attractive terms, or at all nor any assurances that lenders will provide additional extensions, waivers or amendments in the event of future non-compliance with our debt covenants or other possible events of default. Further, there can be no assurance that we will be able to execute a reduction, extension, or refinancing of the debt, or that the terms of any replacement financing would be as favorable as the terms of the debt prior to the maturity dates. There can be no assurance that these plans will be successfully implemented or that they will mitigate the conditions that raise substantial doubt about the Company's ability to continue as a going concern.
The unaudited Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q do not include any adjustments to the carrying amounts and classification of assets, liabilities, or expenses that may result if the Company is unable to continue as a going concern.
While we have noted the conditions above regarding our ability to continue as a going concern, it is important to note that our largest subsidiary, DBMG, is operationally profitable, continues to maintain a strong financial position and remains in good standing with its lenders. Under INNOVATE’s Senior Secured Notes Indenture, DBMG is a restricted subsidiary, not a guarantor, and INNOVATE’s equity interests in DBMG are pledged as collateral.
Capital Expenditures
Capital expenditures are set forth in the table below (in millions):
| Three Months Ended June 30, 2026 | 2025 | Six Months Ended June 30, 2026 | 2025 | |
|---|---|---|---|---|
| Infrastructure | $9.9 | $5.1 | $18.8 | $9.2 |
| Life Sciences | — | (0.1) | — | — |
| Spectrum | 0.5 | 1.1 | 1.1 | 1.6 |
| Total | $10.4 | $6.1 | $19.9 | $10.8 |
Summary of Consolidated Cash Flows
The below table summarizes the cash provided by or used in our activities (in millions):
| Six Months Ended June 30, 2026 | 2025 | Change | |
|---|---|---|---|
| Cash provided by operating activities | $20.9 | $26.3 | $(5.4) |
| Cash used in investing activities | (20.6) | (10.2) | (10.4) |
| Cash used in financing activities | (22.6) | (32.2) | 9.6 |
| Effects of exchange rate changes on cash, cash equivalents and restricted cash | — | 0.8 | (0.8) |
| Net decrease in cash and cash equivalents, including restricted cash and cash classified within assets held for sale | $(22.3) | $(15.3) | $(7.0) |
| Decrease in cash and cash equivalents from assets held for sale | 1.9 | 1.4 | 0.5 |
| Net decrease in cash and cash equivalents, including restricted cash | $(20.4) | $(13.9) | $(6.5) |
Operating Activities
Cash provided by operating activities was $20.9 million for the six months ended June 30, 2026, as compared to $26.3 million for the six months ended June 30, 2025, a decrease of $5.4 million. Cash flows from operations are primarily influenced by changes in the timing of demand for services and by operating margins, but can also be affected by working capital needs associated with our operations. For the six months ended June 30, 2026, the decrease in cash flows from operating activities was primarily driven by our Infrastructure segment, partially offset by an improvement at our Non-Operating Corporate segment. The decrease in operating cash flows at our Infrastructure segment was primarily due to a decrease in working capital from normal business fluctuations in contract-related assets and liabilities, other current assets and liabilities resulting from the timing of regular bill payment activities and ordinary project activity. The net decrease in working capital inflows at our Infrastructure segment was partially offset by an increase in net income after non-cash adjustments. Our Non-Operating Corporate segment's decrease in cash used in operating activities was primarily due to decreases in cash paid for interest and, to a lesser extent cash paid for taxes.
Investing Activities
Cash used in investing activities was $20.6 million for the six months ended June 30, 2026, as compared to $10.2 million for the six months ended June 30, 2025, an increase in cash used in investing activities of $10.4 million. Capital expenditures totaled $19.9 million, or $19.8 million net of proceeds from disposals, for the six months ended June 30, 2026, as compared to $10.8 million, or $9.6 million net proceeds from disposals, for the six months ended June 30, 2025, for a net increase in cash used in investing activities of $10.2 million. The increase was primarily driven by increased PP&E additions in the current period at our Infrastructure segment, and higher PP&E sales in the prior period. In addition there was a $0.2 million increase in cash outflows for the purchase of marketable investments at our Non-Operating Corporate Segment.
Financing Activities
Cash used in financing activities was $22.6 million for the six months ended June 30, 2026, as compared to $32.2 million for the six months ended June 30, 2025, a decrease in cash used in financing activities of $9.6 million. The decrease in financing cash outflows was primarily driven by our Infrastructure segment which had a net decrease in cash outflows from term loan activity of $12.9 million and a net decrease in credit facility related repayments of $0.6 million. The decrease in payments for other debt obligations at our Infrastructure segment was partially offset by increases in payments for other debt obligations at our Spectrum and Non-Operating Corporate segments. Our Spectrum segment had a net increase in cash outflows for other debt obligations and third party financing costs of $2.4 million, related to their recent refinancing, in which the proceeds related to the new $105 million CONX bridge loan facility were used to repay $104.6 million to the 8.50% and 11.45% Spectrum Note holders (inclusive of principal, and exit fees and paid in kind interest capitalized into the principal balance) and $2.8 million was paid for third party refinancing transaction fees. The increase in cash outflows at our Non-Operating Corporate segment was due to the redemption of the remaining $1.9 million in principal amount of the 8.50% 2026 Senior Secured Notes that matured in the current period. For the six months ended June 30, 2026, dividend payments paid by our Non-Operating Corporate segment to the holders of our Series A-3 Preferred Stock and Series A-4 Preferred Stock decreased by $0.6 million, partially offset by an increase in dividends paid by our Infrastructure segment of $0.2 million, as compared to the prior period.
Infrastructure
Cash Flows
Cash flows from operating activities are the principal source of cash used to fund DBMG’s operating expenses, interest payments on debt, and capital expenditures. DBMG's short-term cash needs are primarily for working capital to support operations including receivables, inventories, and other costs incurred in performing on its contracts. DBMG attempts to structure the payment arrangements under its contracts to match costs incurred under the project. To the extent it is able to bill in advance of costs incurred, DBMG generates working capital through billings in excess of costs and recognized earnings on uncompleted contracts. DBMG relies on its credit facilities to meet its working capital needs. DBMG believes that its available funds, cash generated by operating activities and funds available under its bank credit facilities will be adequate to meet all funding requirements for its operating expenses, working capital needs, interest payments on debt and capital expenditures for the foreseeable future. However, DBMG may expand its operations through future acquisitions and may require additional equity or debt financing.
DBMG is required to make monthly interest payments on all of its debt. Based upon the June 30, 2026, debt balance, DBMG anticipates that its interest payments will be approximately $1.1 million for each remaining quarter of 2026.
The DBMG Credit Agreement contains a Change in Control clause, which would constitute an Event of Default, both as defined in the DBMG Credit Agreement, which could accelerate the maturity of the DBMG debt in the future upon certain events, including a sale of DBMG. As the Change in Control clause has not been triggered, the DBMG debt instruments remain classified as non-current as of June 30, 2026, except amounts due within the next 12 months, as originally defined in the DBMG Credit Agreement. Refer to Note 12. Debt Obligations to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information.
New Accounting Pronouncements
For information on new accounting pronouncements, refer to Note 2. Summary of Significant Accounting Policies to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information.
Critical Accounting Estimates
There have been no material changes in the Company’s critical accounting policies during the period ended June 30, 2026. For information about critical accounting policies and estimates, refer to “Critical Accounting Estimates” under Item 7 of our 2025 Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on March 26, 2026.
Related Party Transactions
For a discussion of our Related Party Transactions, refer to Note 17. Related Parties to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference.
Special Note Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q contains or incorporates a number of "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are based on current expectations, and are not strictly historical statements. In some cases, you can identify forward-looking statements by terminology such as "if," "may," "should," "believe," "anticipate," "future," "forward," "potential," "estimate," "opportunity," "goal," "objective," "growth," "outcome," "could," "expect," "intend," "plan," "strategy," "provide," "commitment," "result," "seek," "pursue," "ongoing," "include" or in the negative of such terms or comparable terminology. These forward-looking statements inherently involve certain risks and uncertainties and are not guarantees of performance, results, or the creation of stockholder value, although they are based on our current plans or assessments which we believe to be reasonable as of the date hereof.
Factors that could cause actual results, events and developments to differ include, without limitation: the ability of our subsidiaries (including target businesses following their acquisition) to generate sufficient net income and cash flows to make upstream cash distributions, capital market conditions, our and our subsidiaries’ ability to identify any suitable future acquisition opportunities, efficiencies/cost avoidance, cost savings, income and margins, growth, economies of scale, combined operations, future economic performance, conditions to, and the timetable for, completing current and future acquisitions and dispositions and the successful integration of acquisitions with INNOVATE or the applicable subsidiary, litigation, potential and contingent liabilities, management’s plans, changes in regulations and taxes.
Forward-looking statements are not guarantees of performance. You should understand that the following important factors, in addition to those discussed under the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 26, 2026, and the documents incorporated herein by reference, could affect our future results and could cause those results or other outcomes to differ materially from those expressed or implied in the forward-looking statements. You should also understand that many factors described under one heading below may apply to more than one section in which we have grouped them for the purpose of this presentation. As a result, you should consider all of the following factors, together with all of the other information presented herein, in evaluating our business and that of our subsidiaries.
INNOVATE Corp. and Subsidiaries
Our actual results or other outcomes may differ from those expressed or implied by forward-looking statements contained herein due to a variety of important factors, including, without limitation, the following:
- our dependence on distributions from our subsidiaries to fund our operations and payments on our obligations;
- substantial doubt about our ability to continue operating as a going concern;
- our ability to consummate asset sales on anticipated terms and timing or at all and to realize sufficient proceeds, including from any non-cash proceeds to satisfy our outstanding obligations;
- our ability to obtain FCC regulatory approval for the Spectrum Merger in a timely manner or at all;
- our anticipated business profile following the highly substantial asset dispositions we are pursuing, including the potential absence of material operating revenue and uncertainty regarding the nature of any future operations;
- the impact on our business and financial condition of our substantial indebtedness and the significant additional indebtedness and other financing obligations we may incur;
- the impact of covenants in the Indentures governing INNOVATE’s 2027 Senior Secured Notes, 2027 Convertible Notes, 2026 Convertible Notes, CGIC Subordinated Secured Promissory Note and Revolving Line of Credit, our Third Amended and Restated Certificate of Incorporation and all other subsidiary debt obligations as summarized in Note 12. Debt Obligations to our Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q and any future amendments or other new financing agreements on our ability to operate our business and finance our pursuit of acquisition opportunities;
- our possible inability to generate sufficient liquidity, margins, earnings per share, cash flow and working capital from our operating segments;
- our dependence on certain key personnel including the passing in 2023 of Mr. Barr, our former CEO, President and Director and the successful transition of his management responsibilities;
- bank failures or other similar events that could adversely affect our and our customers' and vendors' liquidity and financial performance;
- our possible inability to hire and retain qualified executive management, sales, technical and other personnel;
- the potential for, and our ability to, remediate future material weaknesses in our internal controls over financial reporting;
- changes in market conditions, including from political regulatory or market uncertainty, changes in foreign exchange rates, interest rates or inflation, supply chain disruptions, labor shortages and increases in overall price levels, including in transportation costs;
- the uncertain effects of U.S. and foreign government actions affecting international trade and economic policy, including changes in volatility in tariffs and trade policies and retaliatory actions, on credit markets, customers, and customer retention, and demand for our products and services;
- increased competition in the markets in which our operating segments conduct their businesses;
- limitations on our ability to successfully identify any strategic acquisitions or business opportunities and to compete for these opportunities with others who have greater resources;
- our ability to effectively increase the size of our organization, if needed, and manage our growth;
- the impact of expending significant resources in considering acquisition targets or business opportunities that are not consummated;
- our expectations and timing with respect to our ordinary course acquisition activity and whether such acquisitions are accretive or dilutive to stockholders;
- the effect any interests our officers, directors, stockholders and their respective affiliates may have in certain transactions in which we are involved;
- uncertain global economic conditions in the markets in which our operating segments conduct their businesses;
- the effects related to or resulting from ongoing and recent geopolitical events, such as the conflicts in Ukraine, the Middle East, and Venezuela, including the imposition of additional sanctions and export controls, as well as the broader impact to financial markets and the global macroeconomic and geopolitical environment;
- the impact of catastrophic events, including natural disasters, pandemic illness and the outbreak of war, or acts of terrorism;
- potential impacts on our business resulting from climate change, greenhouse gas regulations, and the impact of climate change-related changes on the frequency and severity of weather patterns;
- the impact of additional material charges associated with our oversight of acquired or target businesses and the integration of our financial reporting;
- tax consequences associated with our acquisition, holding and disposition of target companies and assets;
- our ability to remain in compliance with the listing standards of the NYSE;
- the ability of our operating segments to attract and retain customers;
- our expectations regarding the timing, extent and effectiveness of our cost reduction initiatives and management’s ability to moderate or control discretionary spending;
- management’s plans, goals, forecasts, expectations, guidance, objectives, strategies and timing for future operations, acquisitions, synergies, asset dispositions, fixed asset and goodwill impairment charges, tax and withholding expense, selling, general and administrative expenses, product plans, performance and results;
- management’s assessment of market factors and competitive developments, including pricing actions and regulatory rulings;
- our expectations and timing with respect to any strategic dispositions and sales of our operating subsidiaries, or businesses, that we may make in the future and the effect of any such dispositions or sales on our results of operations;
- the possibility of indemnification claims arising out of divestitures of businesses; and
- our possible inability to raise additional capital when needed or refinance our existing debt, on attractive terms, or at all.
Infrastructure / DBM Global Inc.
Our actual results or other outcomes of DBMG, and, thus, our Infrastructure segment, may differ from those expressed or implied by forward-looking statements contained herein due to a variety of important factors, including, without limitation, the following:
- adverse impacts from weather affecting DBMG’s performance and timeliness of completion of projects, which could lead to increased costs and affect the quality, costs or availability of, or delivery schedule for, equipment, components, materials, labor or subcontractors;
- cost overruns on fixed-price or similar contracts or failure to receive timely or proper payments on cost-reimbursable contracts, whether as a result of improper estimates, performance, disputes, or otherwise;
- uncertain timing and funding of new contract awards, as well as project cancellations;
- potential impediments and limitations on our ability to complete ordinary course acquisitions in anticipated time frames or at all;
- changes in the costs or availability of, or delivery schedule for, equipment, components, materials, labor or subcontractors;
- changes in economic conditions, including from the impact of inflationary pressures and changes in interest rates;
- adverse outcomes of pending claims or litigation or the possibility of new claims or litigation, and the potential effect of such claims or litigation on DBMG’s business, financial condition, results of operations or cash flow;
- risks associated with labor productivity, including performance of subcontractors that DBMG hires to complete projects;
- its ability to realize cost savings from expected performance of contracts, whether as a result of improper estimates, performance, or otherwise;
- its ability to settle or negotiate unapproved change orders and claims;
- fluctuating revenue resulting from a number of factors, including the cyclical nature of the individual markets in which our customers operate;
- our possible inability to raise additional capital when needed or refinance our existing debt, on attractive terms, or at all; and
- lack of necessary liquidity to provide bid, performance, advance payment and retention bonds, guarantees, or letters of credit securing DBMG’s obligations under bids and contracts, or to finance expenditures prior to the receipt of payment for the performance of contracts.
Life Sciences / Pansend Life Sciences, LLC
Our actual results or other outcomes of Pansend Life Sciences, LLC, and, thus, our Life Sciences segment, may differ from those expressed or implied by forward-looking statements contained herein due to a variety of important factors, including, without limitation, the following:
- our Life Sciences segment’s ability to invest in development stage companies;
- Indebtedness of R2 Technologies that will mature on December 31, 2026 (following the amendment described in Note 22. Subsequent Events);
- our Life Sciences segment’s ability to develop products and treatments related to its portfolio companies;
- medical advances in healthcare and biotechnology;
- governmental regulation in the healthcare industry; and
- our Life Sciences segment possible inability to raise additional capital when needed or refinance its existing debt, on attractive terms, or at all.
Spectrum / HC2 Broadcasting Holdings Inc.
Our actual results or other outcomes of Broadcasting, and, thus, our Spectrum business, which is reflected as held for sale in the Condensed Consolidated Financial Statements, may differ from those expressed or implied by forward-looking statements contained herein due to a variety of important factors, including, without limitation, the following:
- our ability to consummate the Spectrum Merger, on anticipated terms and timing or at all; and
- whether the CONX Affiliate exercises its option under the CONX Affiliate Letter Agreement, whether we exercise our option and the price realized upon any such exercise.
We caution the reader that undue reliance should not be placed on any forward-looking statements, which speak only as of the date of this document. Neither we nor any of our subsidiaries undertake any duty or responsibility to update any of these forward-looking statements to reflect events or circumstances after the date of this document or to reflect actual outcomes, except as required by applicable law.
Controls and procedures
As filed, 1,619 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
Our management evaluated, with the participation of our Interim Chief Executive Officer and Chief Financial Officer, the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 as amended (the "Exchange Act") as of the end of the period covered by this report. Based on this evaluation, our Interim Chief Executive Officer and Chief Financial Officer have concluded that, as of June 30, 2026, our disclosure controls and procedures were effective. Disclosure controls and procedures mean our controls and other procedures that are designed to ensure that information required to be disclosed by us in our reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in our reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
There have been no changes in our internal control over financial reporting that occurred during the quarter ended June 30, 2026, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 6,122 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The Risk Factors set forth below supplement and, as applicable, update, and should be read together with, the risk factors set forth in Part 1, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025. The Company is currently pursuing highly substantial asset dispositions. It has also made changes to its debt arrangements and other liabilities, including following June 30, 2026, and expects to make further changes. These ongoing actions will substantially alter the Company’s business, prospects, cash flow and financial position going forward and all information herein, including information incorporated by reference herein, should be evaluated in light of these changes and potential changes. Refer to Note 22. Subsequent Events for further information.
If we fail to consummate the Spectrum Merger, the Bridge Loan Facility may become due on terms we do not expect to have the resources to satisfy, which could trigger defaults under our debt instruments and materially adversely affect our financial condition, liquidity and ability to continue as a going concern.
The Spectrum Merger involves the transfer of FCC broadcasting licenses held by our Spectrum segment. FCC approval is required for such transfers, and there can be no assurance that such approval will be obtained in a timely manner or at all. Any delay or denial of FCC approval could delay or prevent the consummation of the Spectrum Merger and expose Broadcasting and its guarantors to repayment or acceleration of the Bridge Loan Facility. The FCC regulatory approval process may also impose conditions on the transfer that could reduce the benefits of the transaction.
If we fail to consummate the Spectrum Merger, the Bridge Loan Facility under the New Loan Agreement would remain outstanding and, absent consummation of the Merger by the first anniversary of the Loan Closing Date, Broadcasting would be required to repay in cash an amount sufficient to result in a minimum cash return of 1.5:1.0 on the original principal amount of the Loans, including all accrued and capitalized interest, which the Company does not expect Broadcasting or the guarantors to have the resources to satisfy. In addition, termination of the Merger Agreement would constitute an event of default under the New Loan Agreement, potentially accelerating the Bridge Loan Facility obligations. The closing is subject to conditions that may not be satisfied, including receipt of FCC approval and expiration or termination of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, waiting period, and the Merger Agreement is terminable by either party if the Merger has not occurred by November 29, 2026, subject to extensions to March 1, 2027 and May 29, 2027 if only specified regulatory conditions remain unsatisfied. Any failure or material delay in consummating the Spectrum Merger could therefore trigger defaults or cross-defaults under our debt instruments and have a material adverse effect on our financial condition, results of operations, liquidity and ability to continue as a going concern.
Even if the Merger is consummated, the Company does not expect to receive any cash proceeds from the Spectrum Merger; the Company's retained 25% equity interest in the Surviving Entity would be illiquid absent exercise of the CONX Affiliate's option under the CONX Affiliate Letter Agreement, the timing, price and occurrence of which are uncertain. In addition, the Option Agreement may require the Company to apply net cash proceeds from future asset sales to exercise the option to acquire additional Surviving Entity equity, subject to applicable exceptions and the requirements of our debt instruments, which could limit the proceeds otherwise available for other corporate purposes.
The Spectrum Merger may subject us to risks associated with transition services, dis-synergies, stranded assets, and employee retention.
In connection with the Spectrum Merger, we may be required to provide certain transition services to the purchaser, and any issues, delays or complications in completing such services, including the incurrence of unanticipated costs, could adversely affect our business and financial condition. In addition, as a result of the probable sale, we may incur or experience various adverse effects, including but not limited to (i) greater costs or fewer benefits than anticipated under the sale agreement, (ii) operational or commercial difficulties segregating the divested assets from our retained assets, (iii) disputes with the purchasers regarding the nature and sufficiency of the transition services we provide, (iv) higher vendor costs due to reduced economies of scale or other similar dis-synergies, (v) modified, terminated or scaled back relationships with existing customers or difficulty attracting prospective customers, (vi) diversion of management's attention away from the operations of our retained business, (vii) loss or difficulty in retaining employees due to concerns over future job security or responsibilities, or (viii) losses or increased inefficiencies from stranded or underutilized assets. Any of these risks could have a material adverse effect on our business, financial condition, results of operations, and cash flows.
Retained liabilities and indemnification obligations in connection with the Spectrum Merger could result in unanticipated costs.
In connection with the Spectrum Merger, we may retain certain pre-closing liabilities and may be subject to indemnification obligations under the applicable sale agreements and related ancillary agreements. These retained liabilities and indemnification obligations could result in unanticipated costs and could have a material adverse effect on our financial condition, results of operations, and cash flows. In addition, we remain liable for claims and expenses that may arise related to our business operations prior to the completion of the sales, and we may be subject to contingent liabilities related to the sales that could have a material adverse effect on our financial condition.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2026-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2026-04-01 to 2026-06-30 | $421.6m | us-gaap:Revenues |
| Revenue | 6 months2026-01-01 to 2026-06-30 | $786.4m | us-gaap:Revenues |
| Cost of revenue | 3 months2026-04-01 to 2026-06-30 | $342.1m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2026-01-01 to 2026-06-30 | $653.4m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2026-04-01 to 2026-06-30 | $79.5m | us-gaap:GrossProfit |
| Gross profit | 6 months2026-01-01 to 2026-06-30 | $133.0m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2026-04-01 to 2026-06-30 | $41.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2026-01-01 to 2026-06-30 | $80.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2026-04-01 to 2026-06-30 | $34.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2026-01-01 to 2026-06-30 | $44.5m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2026-04-01 to 2026-06-30 | $27.6m | us-gaap:InterestExpenseNonoperating |
| Interest expense | 6 months2026-01-01 to 2026-06-30 | $52.1m | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months2026-04-01 to 2026-06-30 | $13.1m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2026-01-01 to 2026-06-30 | $16.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2026-04-01 to 2026-06-30 | $10.7m | us-gaap:NetIncomeLoss |
| Net income | 6 months2026-01-01 to 2026-06-30 | −$6.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2026-04-01 to 2026-06-30 | $0.71 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2026-01-01 to 2026-06-30 | −$0.51 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2026-04-01 to 2026-06-30 | $0.74 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2026-01-01 to 2026-06-30 | −$0.51 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2026-04-01 to 2026-06-30 | 13,968,004 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2026-01-01 to 2026-06-30 | 13,360,333 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2026-01-01 to 2026-06-30 | $20.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2026-01-01 to 2026-06-30 | $300.0k | us-gaap:PaymentsToAcquireProductiveAssets |
| Dividends paid | 6 months2026-01-01 to 2026-06-30 | $700.0k | us-gaap:PaymentsOfDividends |
| Cash and equivalents | At period end2026-06-30 | $87.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2026-06-30 | $479.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2026-06-30 | $1.01bn | us-gaap:Assets |
| Current liabilities | At period end2026-06-30 | $1.08bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2026-06-30 | $1.23bn | us-gaap:Liabilities |
| Current portion of debt | At period end2026-06-30 | $553.9m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2026-06-30 | −$243.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001006837-26-000063. Last ingested by Listed: Nov 14, 2026, 23:42 ET. Listed shows no prices and gives no investment advice.